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ABSTRACT
Since the completion of the Human Genome Project in 2003, it has become increasingly apparent
that while genomics has a major role to play in the understanding of human biology, information
from other disciplines is necessary to explain the web of interacting signals that allow our bodies
to function on a day to day basis and respond to rapid changes in our local environment.
One such field, that of metabolomics, focuses on the study of the set of low molecular weight
compounds (metabolites) involved in metabolism. Metabolomic studies aim to quantify the
concentrations of each of these compounds within a subject under particular conditions, resulting
in either information on the physiological effects of a disease or environmental factor (such as a
toxin) on the organism, or the identification of metabolites or groups of metabolites that serve
as biochemical markers for a state or illness.
Whilst metabolite concentrations alone can give great insight into a chosen state, additional
information can be obtained by considering the ways in which metabolites interact with each
other as parts of a larger system. One method of tackling this problem, metabolic networks, is
gaining popularity within the community as it offers a complementary approach to the traditional
biological method for studying metabolism, the metabolic pathway. Construction methods are
varied; ranging from the mapping of experimental data onto pathway diagrams, through the use
of correlation-based techniques, to the analysis of time-series data of metabolic fluxes. However,
while many attempts have been made to capture and visualise the complex web of reactions
within an organism, few have yet succeeded in showing how they can be used to help identify
the metabolites that are most significantly involved in the differences between groups of biological
samples.
This thesis discusses ways in which graphs may be used to aid researchers in both the visu-
alisation and interpretation of metabolomic datasets, and provide a platform for more auto-
mated analysis techniques. To that end, it first presents the background to the relevant topics,
metabolomics and graph theory, before moving on to show how metabolic correlation networks
can be used to identify and visualise differences in metabolism between groups of subjects.
It then introduces Linked Metabolites, a software package that has been developed to help
researchers explain differences in metabolism by highlighting relationships between metabolites
within the metabolic pathways, and to compile those relationships into directed metabolic graphs
suitable for analysis using metrics from graph theory. Finally, the thesis explains how the di-
rected metabolic graphs produced by Linked Metabolites could potentially be used to integrate
data gathered from the same sample using different experimental techniques, refining the areas
of the underlying biochemistry needing further investigation.
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CHAPTER 1
INTRODUCTION
Metabolomics, the study of the set of low molecular weight compounds involved in metabolism,
is an ideal tool for the monitoring the physiological state of a cell or organism. In particular,
its ability to be used non-invasively either in vitro on samples of biofluids (for example blood,
urine, or breath condensates) or in vivo by Magnetic Resonance Spectroscopy (MRS), mean
that it has strong potential in fields such as medical screening, toxicology and environmental
monitoring.
In order to separate groups of subjects within a study (for example diseased and healthy) many
metabolomics experiments aim to identify a list of key compounds, known as biomarkers, whose
concentrations differ substantially between the groups. The identification of biomarkers is often
performed using statistical tools such as Principal Components Analysis (PCA) and can result
in a long list of potential biomarkers, which then have to be checked by hand in order to remove
“the usual suspects”[1], compounds that are involved in processes such as cell death and will
appear to alter in many different diseases.
One way in which biomarkers are validated is through identifying their roles in important
metabolic processes, such as the breaking down of sugars releasing energy (glycolysis). Each
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process, known as a metabolic pathway, has been identified through experimentation over a
number of years and is commonly presented as a metabolic pathway diagram[2]. Unfortunately,
while individual metabolic pathways can be interpreted reasonably easily by eye, the complete
metabolic network in a cell or organism is made up of over one hundred pathways, all of which
are interconnected. As a result of this, the validation of biomarkers is a difficult and time
consuming task.
1.1 Aim and objectives
This thesis will investigate the relationship between biomarkers and the underlying biochemical
processes as represented by the metabolic pathways. As part of this we will explore how exper-
imental data can be visualised in ways that enable the relationship between metabolites to be
easily determined, how automated searching of the metabolic pathways might be implemented
and used to reduce the complexity of biomarker validation, and how, in the future, data from
other -omics approaches, such as genomics or transcriptomics, might be combined and used to
further refine the search space. All of this work is presented as a step towards the long-term
goal of providing a platform for the application of techniques from graph theory to search and
pattern-matching problems in biological networks.
1.2 Thesis organisation and contributions
Chapter 2 provides the background to the area, beginning with a brief discussion of metabolomics
along with some examples of its use and moving on to discuss the challenges facing the field over
the next few years. It then provides an introduction to graph theory and a selection of different
graph structures & metrics, before finally discussing the metabolic pathways and methods for
2
constructing different types of biological networks.
Chapter 3 explains how the background provided in the previous chapter relates to the topic of
the thesis, and formulates the problem it will address.
Chapter 4 gives an example of how correlation networks, built from experimental data, were used
to investigate the metabolic changes taking place in liver tumours in dab, a common flatfish.
It shows how the networks allow the identification of possible relationships between compounds
and how they also allow the researcher to see where changes in those relationships are taking
place between sample groups. It also serves as an example of how metabolomics practitioners
then go on to relate compounds that may be potential markers to the metabolic pathways, in
an attempt to explain the biochemical reasons for their differing behaviour between groups.
Chapter 5 introduces Linked Metabolites, a software package that allows the user to combine
metabolic pathways and then search them for paths between two groups of compounds, forming
what we call directed metabolic graphs. Linked Metabolites is the major contribution of this
work to the field, and is intended to assist researchers with the most time-consuming section
of the biomarker validation process; explaining how compounds seen to be acting as potential
biomarkers are related in the underlying biochemistry. The directed metabolic graphs it produces
also provide a basis for the extension of this work with metrics from graph theory. The chapter
then goes on to discuss different ways in which compounds might be grouped based on the
experimental data, and compares the performance of Linked Metabolites against that of a similar
tool, KEGG PathComp. Finally, it provides an example of the use of Linked Metabolites in the
investigation of a set a ratios that can be used to differentiate between three types of childhood
cerebellar tumour.
Chapter 6 discusses how a graph-based approach to metabolomics might fit into a larger, inte-
grated genomics study. It gives some examples of how directed metabolic graphs can be built
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from gene expression (microarray) data, which could then, in combination with suitable graph
alignment techniques, be used to refine the graphs produced by Linked Metabolites.
Chapter 7 then summarises the work, discusses how it addresses the original problem, and
speculates on how it could be extended in the future.
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CHAPTER 2
BACKGROUND
This chapter presents the background for the thesis. It begins with a discussion of metabolomics,
including examples of its applications in both bioscience and medicine. It then goes on to
introduce graph theory, discussing a number of different graph topologies and the metrics that
can be used to classify them. Finally, it brings the two topics together, describing the ways
in which metabolomics is suited to a graph theory-based analysis approach; this is done with
reference to the traditional method of presenting metabolic knowledge, the metabolic pathway
diagrams, and a method of exploring metabolomic datasets, metabolic correlation networks.
2.1 Metabolomics
In 2005, Hatzimanikatis et al. began a paper by stating that “Metabolism, the network of
chemical reactions that make life possible, is one of the most complex processes in nature.”[3]
It is unlikely that there are many who would dispute this statement; estimates suggest for
example, that as many as 200,000 different metabolites (the low molecular weight compounds
that act as substrates or products in metabolic reactions) may exist within the plant kingdom[4],
although this figure is much lower for animals. The complete set of metabolites found within
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an organism is referred to as the metabolome, although it has been argued that since not all
cells within an organism contain the same set of metabolites the term should actually refer to
the set of metabolites encountered within a cell type[5]. Regardless of whether you subscribe
to the local or global view of the metabolome, metabolomics (as with other -omics technologies
such as transcriptomics for the transcriptome or proteomics for the proteome) is simply the
measurement of the concentrations of its constituent compounds with the aim of determining
the physiological, developmental or pathological state of a cell, tissue, organ or organism[6].
A typical metabolomics experiment involves the following steps:
1. Samples, either tissues, biofluids (blood, urine) or gas condensates (often breath samples
collected as the subject exhales) are gathered and prepared as appropriate for the technique
to be used.
2. High-throughput technologies such as Nuclear Magnetic Resonance (NMR) or Mass Spec-
trometry (MS), which may be used in conjunction with separation techniques such as
liquid or gas chromatography to improve their resolution, are then used to record spectra
for the samples.
3. Peaks in the recorded spectra may be identified and assigned to particular metabolites.
Whether or not this step takes place is determined at least in part by the aim of the
study; be it a metabolomics experiment in the canonical sense, where changes in the
metabolome are quantified and interpreted in terms of the underlying biochemical pro-
cesses, or a metabonomics experiment, in which traditionally the goal was the identification
of a fingerprint for a particular condition or state[7].
4. Multivariate statistical analysis techniques such as Principal Components Analysis (PCA)
are applied to the data to determine whether groups of samples within the dataset (for ex-
ample diseased and healthy) can be distinguished from one another and which metabolites
6
are primarily responsible for the separation.
In recent years, despite the availability of other, more established -omics approaches such as
transcriptomics (the measurement of gene expression via mRNA) and proteomics (the levels of
proteins within a sample), there has been a steady increase in the use of metabolomics within
the biological and medical communities. There are several reasons for this growth. Firstly, it
should be noted that far from being in competition with each other, -omics technologies are
complementary. Cancer, for example, is often ultimately the result of a genetic problem and a
genomics-based technique such as a microarray analysis would help to establish this; however
it would not show us how the genetic change was reflected in the function of the sufferer’s
cells, which is important when considering potential treatments or monitoring their effects.
Secondly, after the initial purchase of a spectrometer a metabolomics analysis can cost as little
as US$1 per sample, this compares very favourably with the cost of transcriptional or proteomic
approaches[8]. Finally, metabolomics is a reasonably portable technique, since while gene and
protein sequences vary between species, the metabolites are largely the same. Thus, rather than
trying to measure the amount of a particular enzyme, requiring the design of protein microarrays
with the appropriate sequences for each organism being studied, it may be much more convenient
to measure the effect on the concentrations of the substrates and products of reactions that the
enzyme catalyses[9].
2.1.1 Applications of metabolomic datasets
While metabolomics has been applied to a range of different fields, two of the most interesting
areas are environmental studies (such as the work on dab liver tumours, see chapter 4), which use
metabolomics to investigate the response of an organism to natural or anthropogenic stresses
under real or simulated environmental conditions[10], and medical applications such as drug
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toxicity, disease diagnosis and the monitoring of response to treatments.
Much of the early metabolomics work focused on plants. In 2000, Fiehn et al.[4] published a
paper that demonstrated the use of metabolic profiling in functional genomics. In their study,
which involved four different strains of Arabidopsis (two different ‘parent’ ecotypes and a mu-
tated version of each), they showed that by performing PCA on the relative concentrations
of 326 metabolites it was possible to separate the samples into their four groupings (although
the separation was much better between the parent strains than between the parents and their
children).
In 2003, Viant et al.[11] published the first application of NMR-based metabolomics to the
aquatic environment. Their study, which focused on Withering Syndrome, a fatal disease that
had already decimated black abalone (a type of edible sea snail) populations in California,
showed that it was possible to distinguish between healthy and diseased red abalone, as well as
those with stunted growth, using metabolomic data from samples of the animal’s foot muscle,
digestive gland and hemolymph tissue. The study also identified several potential biomarkers
for the condition, including decreased levels of phenylalanine, tryptophan, tyrosine & glycine,
and increased levels of formate and homarine.
In 2004, Bundy et al.[12] performed a study to determine if an NMR metabolomic analysis of
relative histidine concentrations, which had previously been identified as a potential biomarker
for copper contamination in semi-field-scale trials, could be effectively used in the field as an
indicator of metal contamination. The study involved three species of earthworm (as does much
of the literature in the area owing to their relative immobility and close contact with their
surround environment[13]), two native and one imported, spread across six sites with varying
degrees of contamination. No species of worm was at all six sites. While the experiments did
show that separations between groups of worms from the different sites could be created based
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on PCA for all three species, the degree of contamination at which the separation took place
differed for each species. The analysis also identified maltose as a potential biomarker for metal
contamination, although while one of the native species of worm showed an increasing relative
concentration of maltose in the more highly contaminated sites, the other species showed a
decreasing level of maltose. This is a good illustration of the need to apply biomarkers carefully
due to differences in metabolism between species.
Metabolomics has a role to play in a whole range of healthcare-related fields; in disease pre-
vention, through studies of how diet and nutrition impact on various forms of illness[14], in
disease diagnosis, where biomarkers for particular conditions can help with their rapid diagno-
sis, and in treatment, both through drug development and selection and through the monitoring
of responses to therapy.
While the primary aim of any preclinical toxicology study has to be to ensure the safety of
any recipients of a new treatment, an important secondary consideration is that “the later
that a molecule or molecular class is lost from the drug development pipeline, the higher the
financial cost”[15]. As such, preclinical toxicology studies require a careful balance to be struck
between assuring the rapid loss of dangerous drugs and permitting those that have clinical
benefits to pass through the development process. Toxicity studies typically generate clearly
definable endpoints such as clinical signs or histopathology and can be arrived at reasonably
quickly due to high dosage; however, these studies tend to take place after the in vivo testing
of the effectiveness of the compound and those effectiveness tests seldom have as many robust
endpoints that could be used as early warnings of potential toxic effects and frequently take
several weeks to complete[1]. Metabolomics can therefore, play an important role in the drug
development process by allowing the early screening of biofluid samples from the efficacy test
animals for biomarkers of toxic effects. While these markers may not themselves be sufficient
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evidence to stop the development of a drug, they can be used to suggest target organs for later full
toxicology studies. Metabolomics also has a role to play in the later, testing phases of the drug
development process. Here, biofluid samples from the test subjects can be used to ensure the
absence of toxic effects, helping to avoid situations such as that seen in 2006 when six volunteers
suffered multiple organ failures after taking part in the trial of a new anti-inflammatory drug[16].
Although the non- or minimally-intrusive nature of metabolomics of biofluids lends itself to
use in clinical practice, a great deal of preclinical work has also been done to try and identify
biomarkers and understand the metabolic processes going on in diseases. Metabolomics has for
example been used to distinguish between different types of tumour cell lines for a number of
years[8]. The question remains however as to how reflective of a tissue an extracted sample for
metabolomic analysis can be when it has potentially undergone any number of non-biological re-
actions associated with the extraction procedure[1]. One variant of NMR metabolomics, Magic
Angle Spinning (MAS) avoids this problem by allowing the experiment to be performed on
a small sample of intact tissue, rather than an extract. This has the advantage that all the
metabolites are still in-situ within the cellular structures that normally contain them and the
risk of them undergoing additional reactions is much reduced. They can also be related to the
histology[15]. Magic Angle Spinning also allows water and lipid soluble metabolites to be ob-
served simultaneously, a process that would otherwise require separate extraction procedures[8].
Rapid and unobtrusive disease diagnosis and screening is one of the most attractive features
of metabolomics in a clinical setting and much work has been published on the topic. In
2002 for example, Brindle et al.[17] showed that it was possible to diagnose and determine the
severity of coronary heart disease in patients using NMR of serum samples. In 2005, Kenny
et al.[18] identified a pair of rules involving three key metabolite concentrations that could
be used to diagnose pre-eclampisa from the blood plasma of pregnant women; early diagnosis
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is of great importance in such cases as the potential therapies are most likely to be effective
before the clinical presentation of the disease. Coen et al.[19] have shown that it is possible to
distinguish patients with bacterial meningitis from those with viral meningitis based on NMR of
cerebrospinal fluid, a step that can be key in ensuring the patient receives the correct treatment
and therefore has the best chance of survival. Finally, Carraro et al.[20] have shown that exhaled
breath condensate can be used to distinguish children with asthma from those without.
Abnormal brain masses, both malignant and benign, pose difficult diagnostic problems and
require critical therapeutic decisions that can involve risk and possible damage to the patient[21].
This is a particularly important issue in children, where brain tumours are a leading cause of
cancer-related death and the tumours seen differ from those in adults[22]. While Magnetic
Resonance Imaging (MRI) is widely used for determining the extent of a mass and to provide
an initial diagnosis, surgical biopsies are still the gold standard for diagnosis[23]. However, not
all masses are cancerous[21] and many that are display a high degree of heterogeneity meaning
that a histopathological diagnosis from a single site may not fully characterise the bulk of the
tumour[23]. As such, there is a need within oncology for a non-invasive technique that can serve
as a guide for biopsy procedures or provide indications as to whether abnormal masses are likely
to be cancerous to assist with treatment planning and reduce the need for unnecessary surgery.
Magnetic Resonance Spectroscopy (MRS) allows a low-resolution NMR metabolomics experi-
ment to be performed non-invasively on a patient’s tissues using a conventional MRI scanner.
While it had been shown as early as the mid-1990s that MRS could be used to distinguish be-
tween the four most common types of brain tumour (meningioma, astrocytic, oligodendroglioma
& metastasis, and cysts) in adults using pattern recognition techniques[24, 21], its adoption into
routine clinical usage has been hampered by a lack of available data and of simple rules for
diagnosis that can be easily applied by radiologists. These issues are now beginning to be ad-
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dressed, both through work such as that by Harris et al.[25] which uses ratios of the heights of
key points in a spectrum to distinguish between different types of childhood cerebellar tumour
with parameters that can be easily updated as more data becomes available (this work is the
basis for the example usage of Linked Metabolites, see chapter 5), and through multi-centre
databases such as that being produced by the eTumour project[26] or distributed database and
classification systems such as HealthAgents[27]. Even so, despite its potential, data obtained
from MRS can not yet be used independently because of significant overlap and non-specificity
of the results[28].
2.1.2 Challenges facing metabolomics
The metabolism of an organism (as we have seen from the applications to environmental studies)
is extremely sensitive to the environment around it (factors such as availability of food, tempera-
ture and local pollutants) as well as to its own biological characteristics (age, sex etc.). As such,
many metabolomics studies suffer from noise due to biological variation and experiments must
be carefully planned to try and ensure that all the subjects are as closely matched as possible in
every respect save the factor under investigation. While such approaches can help to ensure that
the biomarkers identified are indeed due to the factor under investigation, they also introduce
the risk that the markers may only be applicable under a very narrow subset of conditions and
in a particular location. It has been suggested that these difficulties can be overcome by defin-
ing a Normal Metabolic Operating Range (NMOR) for an organism at a particular site, that
being an area of the multi-dimensional metabolic space that contains 95% of the individuals of
a population at that site and then describing markers as a deviation relative to that space[10].
Alternatively, it has been proposed that composite biomarkers should be utilised, groups of
changes that together can be used to characterise the change in metabolism, thus reducing the
effect of noise on any one metabolite concentration due to external factors[29]. Even so, much
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work remains to be done in this area.
Metabolomics practitioners must also address the problem of “the usual suspects”[1]; compounds
that frequently appear in the literature as biomarkers for a huge range of conditions. These com-
pounds, which include molecules such as citrate, creatine, glucose and lactate are actually often
related to other cellular processes, such as energy metabolism or apoptosis, and hence frequently
appear altered in organisms experiencing some type of stress. Thus, while these compounds may
indeed be altered in the conditions under investigation, they are an important reminder that
metabolomics needs to focus on the most specific markers to a particular condition, and that
the metabolites driving pattern separations in PCA are not necessarily the most interesting
or appropriate for use as biomarkers[1]. The natural solution to this problem lies in relating
the biomarkers to the underlying biology of the system (see chapter 5), both by placing them
in the context of biological processes that are already known to be involved in the condition
under investigation, and potentially by using the presence of particular markers to infer new
knowledge about a particular condition based on biological processes that have been investigated
elsewhere. Traditionally, these comparisons are performed using a set of graphs known as the
metabolic pathway diagrams (for a description of the metabolic pathways, see section 2.2.6), as
such the following sections will provide a brief introduction to graph theory before returning to
the biology in order to discuss some of the ways in which experimental data can be presented
as a graph.
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2.2 Graphs as representations of real-world systems
2.2.1 What is a graph?
In mathematics a graph is a collection of points (commonly referred to as nodes or vertices)
that are connected by a set of links (either called edges if the link is bidirectional or arcs if the
link only applies in a single direction). More formally a graph G = (V,E), is a mathematical
structure consisting of two sets V and E[30]. The elements of the set V are the nodes (or
vertices) of the graph, while the elements of the set E are pairs of nodes representing the start
and end points of the edge. If the graph is directed, then the elements of E are an ordered pair;
in this case the directed edge (or arc) runs from the first node in the pair (the source) to the
second (the target).
In real-world contexts, graphs are often, although by no means exclusively, used to represent
systems where some kind of transfer is involved; these include communications networks where
nodes (senders or receivers) exchange information, power distribution networks, in which nodes
commonly represent power stations, distribution units such as sub-stations or consumers and
the edges represent power lines, and transportation networks, where nodes commonly represent
stations, airports or cities and edges represent the tracks, flight paths or roads between them.
Graph-based models are commonly used to solve a wide range of problems, from network routing
to epidemiology and the determination of the most efficient order for robots to place components
onto printed circuit boards.
2.2.2 The bridges of Ko¨nigsberg
Graphs have been used in the mathematical modeling of real-world systems since the early
eighteenth century. The first recognised use of a graph as a modeling technique was in the
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1730’s when the Swiss-born mathematician Leonhard Euler used it as the basis for his solution
to the Ko¨nigsberg bridge problem. The problem is as follows: in the city of Ko¨nigsberg, on the
banks of the Pregel, there are seven bridges (Figure 2.1). Is it possible for a man to walk across
all seven bridges and never cross the same bridge twice?
Euler’s solution to the problem was beautifully simple, rather than taking the approach used in
coffee shops throughout the city and attempting to find a path that crossed all seven bridges,
he decided to try to prove whether or not such a path could ever be found. In order to achieve
this he drew out the map of the city in a simplified form, as a graph (Figure 2.2), to which he
applied the following reasoning:
1. Nodes in a graph that have an odd number of links must be either the starting point or
the end point of a path.
2. A single, continuous path covering every edge in a graph can only have one starting point
and one end point.
3. Therefore, no single, continuous path covering every edge in a graph can exist if that graph
has more than two nodes with an odd number of links.
In the graph of the Ko¨nigsberg bridges, Euler noted, there were four nodes with an odd number
of edges and therefore there could be no route that crossed all of the seven bridges exactly once.
In the 140 years that followed the publication of Euler’s solution to the Ko¨nigsberg bridge
problem, nobody ever found a route across the seven bridges. It wasn’t until 1875, when the
townsfolk built a new bridge between the banks of the river (thus making two of the four nodes
even) that a walk fulfilling the criteria was finally found.
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Figure 2.1: A map of the city of Ko¨nigsberg in the eighteenth century.
Reproduced from [31].
Figure 2.2: A graph representation of the bridges of Ko¨nigsberg. The
dotted edge represents the 1875 bridge.
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2.2.3 Small worlds
By the mid 1960’s the idea that how people were connected to each other on a local level had
an important effect on the overall structure of the society as a whole was already well accepted
by sociologists. The use of random graphs as models of large social systems was also beginning
to become more popular (indeed sociology was one of very few areas outside of mathematics
where graph theory was actively used as an analysis technique at the time). Initial work by Pool
and Kochen[32], which was originally written in 1958 but didn’t appear as a published work for
another two decades, had suggested that in random graph models of human contact networks
(where nodes represent individuals and links represent a relationship between them such as a
friendship, business relationship or a familial tie) if each person knew, on average, 1000 other
people then most people should be able to be linked to each other via a chain of at most two
intermediaries. This result appeared to agree well with the reasonably common “small world
phenomenon”; the experience of meeting a person who you believe to be a complete stranger
and discovering that you have a common acquaintance. Such a discovery is often accompanied
by the exclamation “It’s a small world!”
In 1967, sociologist Stanley Milgram (who was by this point a rather controversial figure in the
field following his research into the human response to authority figures) began an experiment
designed to investigate the length of chains linking individuals in real social groupings. This
was an experiment that he would repeat in greater detail and with a large sample two years
later[33]. In his experiments Milgram asked groups of volunteers to attempt to pass a letter
to a target person, a Boston stockbroker, identified by his name, address, occupation, place of
work, college, year of graduation, military service dates, wife’s maiden name and hometown.
The only stipulation was that the letter should be passed only to a person known to the sender
on a personal basis and whom the sender believed was more likely to know the target than the
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sender themselves. In addition to the passing of the letter, participants were asked to add their
name to a list that accompanied the letter (to prevent the creation of loops) and also to send a
card back to Milgram so that he could track chains that were incomplete as far as was possible.
The 296 initial volunteers for the 1969 study formed three groups, blue-chip stockholders from
Nebraska, randomly selected individuals from Nebraska, and randomly selected individuals from
the Boston area. Of these initial volunteers, approximately 23 actually passed on the letter and
therefore began a chain. Ultimately 13 of the letters reached the target recipient.
The mean chain length across all three groups was 5.2 steps; while this is considerably larger
than Pool and Kochen’s figure of two, it is still small compared to the size of the population
of the United States at the time (approximately 200 million). Perhaps more impressive is the
fact that the figure didn’t alter hugely with geographical area, with the Boston random group
having a mean chain length of 4.4 compared to a mean chain length of 5.4 for the Nebraska
stockholders and a mean chain length of 5.7 for the Nebraska random group. Milgram’s results
were the first study into what is now commonly referred to as the “six degrees of separation”,
although that term was never used by Milgram himself, it originated instead in John Guare’s
1991 play of the same name[34].
In 1973, around five years after Milgram’s experiments, Mark Granovetter published a paper
based on research he had performed as part of his doctoral dissertation[35]. For his study,
Granovetter questioned a number of professional, managerial and technical workers living in a
Boston suburb; each of the subjects had recently changed job and Granovetter was interested in
how they had come upon the information that led to their new positions. In those cases where
the information had come through a contact, Granovetter asked the subjects how regularly they
saw that contact based on the following scale: often = at least twice a week, occasionally =
more than once a year but less than twice a week, rarely = once a year or less. Over half of the
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subjects reported that they only saw the contact occasionally and additionally, in many cases
indicated that the source of the information was not someone in their current network of contacts.
Instead the contact was commonly a former college friend or an ex business contact such as a
former employer. When tracing the original source of the information back through the contact,
Granovetter discovered that in the vast majority of cases (over 80%) the contact either knew
the source of the information directly, or were within one intermediary of them. Granovetter’s
research showed two things; firstly that ‘new’ information within a social network is unlikely to
come from those people that you interact with on a regular basis, those with whom you have a
‘strong’ tie, as it is likely that you have access to the same information sources. Secondly, that
it is likely the person you do get such information from will be someone you only have a ‘weak’
tie to, an occasional contact who moves in another circle of people and who acts as a bridge
between you and that group. It is that remote group who will have access to information that
is different to your own. The presence of this type of bridge in social networks had two main
implications; firstly, that the larger-scale, macroscopic structure of the system could be at least
as important as the microscopic structure surrounding the subject, but also that the structure
of some networks may differ in very significant ways from that of the random graphs that were
being used to model them on a large scale.
MTV’s “Jon Stewart Show” might seem an unlikely source for an academic idea to be brought
squarely into the public eye; however it was on an edition of that programme in 1994 that
three students of Albright College, Pennsylvania grabbed the attention of the audience with
their ability to link the actor Kevin Bacon, who they claimed was the centre of the Hollywood
universe∗, to any other actor or actress suggested to them[34]. The “six degrees of Kevin Bacon”
as the game became known is played as follows: first, select an actor or actress. The object of
∗Kevin Bacon is not actually the best connected actor in Hollywood, that honour goes to Rod Steiger with
Bacon ranking 1049th (based on the IMDB in June 2004).
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the game is to link that person to Kevin Bacon via a chain of intermediaries they have worked
with on the big screen. As an example, consider Star Trek’s DeForest Kelly; Kelly worked with
Christian Slater on “Star Trek VI” in 1991 and Slater would later work with Kevin Bacon on
“Murder in the First” in 1995.
A few months after the programme aired, a web-based version of the game, “The Oracle of
Bacon”[36] was created by two computer scientists from the University of Virginia. The website
used information from the Internet Movie Database (IMDB)[37] to calculate the shortest path
from an actor to Bacon. Borrowing from a similar game played by academics, in which people
linked themselves to Paul Erdo¨s via coauthorships and then assign themselves a number equiv-
alent to the length of the shortest path[38], the site also came up with ‘Bacon numbers’ for each
actor. In the earlier example, DeForest Kelly was linked to Kevin Bacon in two steps, hence he
has a Bacon number of two. There are of course, plenty of other examples; Kyle MacLachlan
for instance was in “Dune” with Max von Sydow, who was in “Minority Report” with Tom
Cruise. Cruise acted alongside Kevin Bacon in “A Few Good Men” and so Kyle MacLachlan
has a Bacon number of three. While such games are fun they are included here for a good
reason; which is that just like Milgram’s letters or Granovetter’s contacts in the labour market,
they display a surprisingly short average path length between individuals. According to “The
Oracle of Bacon” the mean path length in the “six degrees of Kevin Bacon” is 2.946 (based
on the IMDB in June 2004), while the mean path length for coauthorships with Paul Erdo¨s is
4.65[39].
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In 1998, Duncan Watts and Steven Strogatz proposed a new graph model, one which encap-
sulated both the highly clustered nature of regular lattices and the short average path length
seen in random graphs[40]. The model was called the “small-world network”, a reference to the
small-world phenomenon that it displayed.
In order to generate small-world networks, Watts and Strogatz started with a standard ring
lattice containing n nodes each with k edges. The networks were sparse, meaning that the
number of nodes was far greater than the number of edges per node, however not so sparse that
the graphs were in danger of becoming disconnected (having isolated fragments that are not
connected to the rest of the structure). They then proceeded to rewire each edge at random,
with a probability p. By altering the value of p, Watts and Strogatz were able to investigate
how the degree of randomness they introduced into the graph affected two key parameters; the
average path length, L(p) and the clustering coefficient C(p).
L is defined as the average shortest path length between all pairs of nodes in the graph. C is
defined locally for a node v, with kv neighbours (nodes connected to it by a single edge) and Ev
edges between its neighbours by:
C =
Ev
1
2kv(kv − 1)
(2.1)
This can then be averaged to give C for a graph containing n nodes:
C =
∑n
v=1
Ev
1
2
kv(kv−1)
n
(2.2)
In regular lattices, there is no rewiring and therefore p = 0. In these cases the degree of clustering
C(0) is high, while the average path length L(0) grows linearly with n. By comparison, in a
random graph, where every edge is placed at random p = 1. The degree of clustering C(1) for
21
a random graph is low and the average path length L(1) only grows logarithmically with n.
While the logical assumption based on these boundary conditions might be that a large average
path length always accompanies a large clustering coefficient and vice versa, Watts and Strogatz
found that for a broad range of values of p, graphs were produced in which L(p) was nearly
as small as it is in random graphs and yet C(p) was still considerably larger than in random
graphs. The reason for this was that for small values of p, each rewiring, while only having a
minor effect on the degree of clustering of the system as a whole, would reduce the distance
not only between the source and the target nodes of the rewired edge but also between their
neighbours, the neighbours of their neighbours, and so on. An important implication of this is
that the change from the highly clustered lattice to a small-world would be almost imperceptible
at a local level, since the degree of clustering remained largely unchanged.
Watts and Strogatz then checked their results by measuring L and C for three well-studied
graphs; the network of collaborations between actors, the electrical power grid of the western
United States, and the neural network of the nematode worm Caenorhabditis elegans. In all
three systems they found the same characteristic low average path lengths combined with a high
degree of clustering, demonstrating that far from being a fluke of social networks, the small-world
phenomenon was probably common to many large, sparse networks in nature. The small-world
property is displayed by the directed metabolic graphs in chapter 6.
2.2.4 Scale-free networks
In 1999, Re´ka Albert, Hawoong Jeong and Albert-La´szlo´ Baraba´si published the results of a
study they had performed while investigating the topology of the World-Wide Web[41]. It should
be noted at this point that the World-Wide Web, the network of interconnected documents that
are commonly accessed through a browser such as Mozilla Firefox or Microsoft Internet Explorer,
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is distinct from the Internet, the hardware on which the documents are stored. In order to
gather data on the topology of the web, Albert, Jeong and Baraba´si built a piece of software
commonly known as a web spider; spiders gather information on web pages by recursively
following URLs and adding the pages they discover to a database as they proceed. Using the
topological information gathered by their spider (which they had set to explore the University
of Notre Dame’s domain, nd.edu), Albert, Jeong and Baraba´si began to investigate the in and
out-degree distributions of the system (since a hyperlink is a directed concept, running from one
page to another, each node will have a number of links that head into it, the in-degree of that
node, and a number of links leaving, the out-degree). They discovered that the distributions of
both the in and out degrees across the graph as a whole differed significantly from both those
predicted by Erdo¨s and Re´nyi for random graphs, which would be expected to form a Poisson
distribution, and from that of the small-world networks of Watts and Strogatz. Instead, the
distributions formed a power-law; meaning that for the vast majority of nodes the number of
links was very small. As the number of links increased, the probability of a node having that
number of links dropped logarithmically resulting in very few highly connected nodes, which
dominated the topology of the graph.
On further investigation, Albert, Jeong and Baraba´si found that although the degree distribution
of their data did not match with that of small-world networks, the data did form a small-world as
it displayed the characteristic short average path length (11.2 steps for the nd.edu domain, which
contained 325,729 nodes and 1,469,680 links). The reason for this was the few highly connected
nodes (or hubs) in the system, which acted as short-cuts between otherwise distant parts of the
graph. Albert, Jeong and Baraba´si’s “scale-free” graphs, so called because of the several orders
of magnitude over which the degree distributions displayed a power law tail, quickly became
a topic of great research interest, with several groups worldwide reporting them in a diverse
range of systems; including the routing topology of the Internet[42], metabolic networks[43],
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and social networks including the network of scientific collaborations[44], the network of human
sexual contacts[45] and the terrorist cell responsible for the September 11th attack on the World
Trade Center in New York[46].
Scale-free networks appeared to be common in nature, but what caused them and their unusual
degree distribution? As a follow-up to their work describing scale-free networks, Baraba´si and
Albert published a paper arguing that a combination of network growth over time and preferen-
tial attachment could result in just such a graph[47]. Baraba´si and Albert noticed the following:
in the graphs normally used to model large systems (either the random graphs of Erdo¨s and
Re´nyi or more recently the small-world networks of Watts and Strogatz) the size of the system
is fixed at the time of its creation. A graph is generated, which contains N nodes, and these
are then either connected with a given probability or formed into a lattice that is then rewired.
In real-world systems this is seldom the case; the core of a network will form and it will then
expand, with new nodes being added over time. They also noted that rather than being con-
nected at random to other nodes in the graph, a new node, upon joining the network is more
likely to be connected to some of the existing nodes than it is to others. Actors staring in their
first movie for example, are likely to be working alongside more established figures rather than
in a cast comprised entirely of newcomers. In the same way, a new website is far more likely to
link to sites such as Google or Amazon than it is to a page describing sheep farming methods
in the Ukraine, unless of course it is about a similar topic. In real-world systems it seemed, the
“rich get richer”.
Based on their observations, Baraba´si and Albert proposed the following growth model for scale-
free networks (Figure 2.3 – Figure 2.6). Start with a small number of nodes, m0. Now begin to
add additional nodes to the graph one at a time. As each node is added create edges between it
and a number of the existing nodes in the graph less than or equal to the number of nodes that
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Figure 2.3: Early stage of a scale-free network. This network began with 2
nodes connected by a single edge. With each new node either 1 or 2 edges
were added giving an effective m of 1.5.
Figure 2.4: The network after 18 time-steps (now containing a total of 20
nodes). At this stage nodes 0, 1, 2 and 3 can be seen to be emerging as
hubs.
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Figure 2.5: The network after 48 time-steps (a total of 50 nodes).
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Figure 2.6: The probabilities of a node having degree k for 1 ≤ k ≤ 100
as taken from the completed scale-free network of 100,000 nodes. The
trendline is for a power law with the equation P (k) = 7.4k−2.998
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were initially placed. Select the nodes to which the edges will be attached based on a probability
that is individually scaled, (for each node) according to its degree at that time. Specifically, at
any given time t the graph contains n nodes and the probability of attachment to node i, which
has degree ki, is given by:
∏
(ki) =
ki∑n
j=1 kj
(2.3)
While Baraba´si and Albert’s model does generate scale-free networks, it has problems. It does
not state how to perform the preferential attachment in the case of the initial graph (where
there are no edges) and it can only generate graphs where the exponent of the power law is 3
(in real-world systems this parameter can vary)[48]. A more mathematically rigorous process,
based on Baraa´si and Albert’s criteria, is the LCD model of Bolloba´s and Riordan[49].
The LCD growth model differs from Baraba´si and Albert’s in several ways; firstly self-loops
(edges that link a node to itself) are allowed, as are multiple edges between a pair of nodes.
These features, which are not created by the Baraba´si-Albert model, can be seen in real-world
networks in situations such as a webpage linking to itself (often found in contents tables for long
documents) or as multiple links between two pages (for example references to another topic from
different parts of an online encyclopedia article). In order to allow the creation of self-loops, the
probability of attachment to each node in the graph has to take into account the contribution
to the degree distribution made by the outgoing half of the edge being added. As such, the
probability that a given node, V (s) should be the target of one of the edges from the node being
added in the current time-step, V (t) is given by:
p(Edge(V (t), V (s))) =

d
Gt−11
V (s)
2t−1 1 ≤ s ≤ t− 1
1
2t−1 s = t
(2.4)
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Where dGt−11 V (s) is the degree of node V (s) in the graph at the previous time-step.
It should be noted that since the outgoing portion of each new edge being added to the graph
counts towards the degree of the source node, V (t) the probabilities for each node need to
be recalculated as every edge is added and not just for each time-step as is the case in the
Baraba´si-Albert model.
The second major difference between the two models is in the state of the initial graph; under
the LCD model the initial graph is empty (it contains no nodes or edges) or it only contains a
single node with a self-loop. This combined with the new formula for determining which node
should be the target of the edge being added means that unlike in the Baraba´si-Albert model
there is never any ambiguity over how the preferential attachment should take place (no nodes
exist with degree zero).
Albert, Jeong and Baraba´si went on to study the vulnerability of the networks generated using
the Baraba´si-Albert model to random failures and targeted attacks[42]. They found that in
random graphs, the failure of a small fraction of the nodes caused a noticeable increase in the
diameter of the graph (the length of the shortest path between the two most distant nodes in
the graph) but that it made no difference to the rate of change of the diameter if the nodes
that failed were selected at random or as the result of a targeted selection process. In scale-free
networks by comparison, the effects of random failures were much less pronounced, however
targeted removal of the most connected nodes caused a rapid increase in diameter. The effect of
the removals on the structure also differed, with failures in the random graphs causing them to
fragment at a given threshold, whereas failures in the scale-free networks initially only caused
the size of the largest cluster to gradually decrease, with fragmentation only taking place when
the largest cluster became very small. In a targeted attack scenario however, the effect of node
removals on scale-free networks is similar to that observed in random graphs but it occurs at a
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much higher rate.
The reason for this difference in behaviour was the topology of the graphs. In random graphs,
where the degree of each node is approximately the same, all nodes contribute equally to the
network’s connectivity. As such, the removal of a node will always have an effect on the diameter
of the system and that effect will be similar regardless of the node selected. In scale-free networks
by comparison, the vast majority of the nodes are of low degree and therefore play a very minor
role in the connectedness of the graph. As such the removal of a node at random, which is highly
likely to be a node of low degree, will have a negligible effect on the diameter of the graph. In a
targeted attack however, a hostile agent can choose to remove one of the few, highly connected
hubs; in this case a much larger than normal proportion of the paths through the graph would
be lost, leading to a rapid rise in the diameter of the system.
Based on their studies of the World-Wide Web, Albert, Jeong and Baraba´si had shown over
the course of two years that scale independence existed in real-world, large-scale systems. They
has also demonstrated that such systems were resilient to the random failure of a significant
fraction of their nodes, and developed a growth model that explained both their evolution over
time. Additionally, they had offered an explanation as to why other traditional models had
not shown similar behaviour. Now they moved away from the web and began working with
a set of important biological graphs, metabolic networks[43] (for an introduction to metabolic
networks see section 2.2.6). For this study Albert, Jeong and Baraba´si joined with two biologists
from Northwestern University in Chicago, Ba´lint Tombor and Zolta´n Oltvai. Using data from
the WIT (now ERGO) database, they built graphs of the metabolic processes predicted to be
taking place in 43 different organisms, based on their annotated genomes. Analysis of the graphs
showed that they did indeed possess the characteristic power-law degree distribution of scale-free
networks; furthermore, it showed that the substrates acting as hubs in the metabolic networks
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were practically identical across all the graphs, despite only 4% of the complete list of substrates
being present in all 43 systems (the directed metabolic graphs presented in chapter 6 are also
scale-free). The diameter of the networks showed almost no variation with the complexity of
the organism, which given the average value of just over three steps made metabolism a very
small-world indeed.
The scale-free network model seemed to fit with a wide range of metabolic systems, but was it
solely responsible for their topology? Two years later, and now working with Ravasz, Somera
and Mongru, Oltvai and Baraba´si published another paper about the structure of metabolic net-
works, this time discussing how they apparently differed from the standard scale-free model[50].
Looking at the same 43 systems, they showed that the clustering coefficients of the graphs were
an order of magnitude higher than was predicted by the scale-free model. This suggested that
the traditional, biologists’ viewpoint of metabolism as a modular system, consisting of strongly
linked groups of nodes with weaker ties between them (much like Granovetter’s model of the
labour market), may also be an important element in the topology of metabolic networks. To
explain this phenomenon, Ravasz et al. proposed the ‘hierarchical network’, a scale-free system
made up of repeating, nested groups of nodes rather than individuals thus allowing both a high
clustering coefficient and a power-law degree distribution.
2.2.5 Metrics for the determination of network structure
The range of metrics that can be used in the determination of network structure is huge and
a small section in a document such as this can not hope to give any more than a superficial
coverage of the topic. With this in mind the following section attempts to briefly discuss some
very basic metrics and their uses, and then moves on to cover two more complex metrics that
are likely to be of use within the field of metabolomics. For a more complete review of metrics
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and how they relate to graph structure, the reader is directed to the papers by Newman[51],
Albert[52] and Dorogovtsev[53].
A number of very simple metrics can give a surprising amount of important information about
the structure of a graph. The numbers of nodes and edges alone can for example, be used
to suggest how dense the graph is and whether it is likely to be a single, large structure or
a collection of fragments. Knowing the degree of each node, the number of edges that are
incident to it, is also important; the degree distribution for a graph, node degree plotted against
the probability that a node in the graph has that degree, can be suggestive of many types of
architecture. A Poisson distribution for example, might indicate a random structure, whereas a
distribution that is sharply spiked at a particular value is more suggestive of a regular structure
such as a lattice. It might also indicate a graph that has evolved from a regular structure such as
the small-world networks of Watts and Strogatz. A degree distribution that follows a power-law
is often considered indicative of a scale-free system, although caution is advised as many systems
have been reported as scale-free based on questionable fits of power-laws to the data. In directed
graphs, the degree of each node may be subdivided into an indegree, the number of arcs leading
into the node, and an outdegree, the number of arcs leaving it. The indegree and outdegree
distributions can further assist in the determination of structure by suggesting features such
as layered structures, where one group of nodes within the graph feeds into another. Paths
between nodes play an important part in many graph applications and the determination of
structure is no exception to this; the network diameter, the length of the longest shortest path
between two nodes within the graph, and the average path length between all node pairs in the
graph, can be used to help separate small-world structures (both Watts/Strogatz and scale-free)
from others. Another path metric, betweenness centrality, is the fraction of the shortest paths
between all pairs of nodes within the graph that pass through the node or edge for which it is
being calculated. High betweenness centrality values indicate that the node or edge may be a
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‘bottleneck’ in the graph and that the structure may consist of groups of nodes connected by
a few key elements (this is particularly interesting when considering how automated searches
might identify chains of reactions responsible for observed biological effect, see chapter 5). The
level of grouping of the nodes within a graph can also be investigated using clustering coefficients,
a measure of the extent to which the neighbours of a node are also connected to each other. A
low average clustering coefficient might indicate a tree structure or random graph, while higher
values would suggest lattices or, as above, groups of nodes that are densely connected within
themselves but only connected to each other by a few links. Figure 2.7 shows an example of
how these simple metrics might be used to distinguish between some of the graph structures
discussed.
While metrics such as the network diameter aim to describe the overall structure of the network
under investigation, other metrics attempt to describe how the local environment around the
nodes might appear. One such method, Triadic Census, was proposed by Holland and Leinhardt
in 1970[54]. A triadic census is a survey of the graph for the sixteen unique configurations of
three nodes and the arcs between them (Figure 2.8), and the comparison of the frequencies of
occurrence for each of these structures against a set of ‘expected’ frequencies for a random graph
of the same size. The sixteen triads used during the triadic census are not the only possible
ways of linking three nodes with arcs; if you consider each of the nodes to have a label and
therefore be different from the others, then there are 64 possible configurations. The triads are
an example of the graph isomerism problem, the way in which two structures can appear to be
different because of their layout or numbering but are identical from the structural point of view
(Figure 2.9).
Motif search[55] uses the same ideas as triadic census but applies them to subgraphs of size n;
effectively replacing the dictionary of sixteen, three node structures with that of the n node
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Tree Random Watts / Strogatz Scale-free
Does the degree distribution
display a power-law?
YesNo
Does the network display a
short average path length?
Does the network display a
low degree of clustering?
Yes No
No Yes
Figure 2.7: An example of how a collection of simple metrics can be used
to guide the determination of network structure.
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003 012 021U 021D
102 021C 030T 030C
111U 120U 120D
120C 201 210 300
111D
Figure 2.8: The complete set of triads used during triadic census. The
numbering system xyz describes the triads based on x, the number of pairs
of nodes linked by a bidirectional arc, y, the number of pairs of nodes linked
by a unidirectional arc, and z, the number of unlinked pairs. The letter
is used to further distinguish between the shapes, up, down, transitive or
cyclic.
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1 2
3 4
1 2
3 4
Figure 2.9: An example of the graph isomerism problem. The graphs on
the left and in the centre of the figure appear to be different, but if the
numbering is ignored and the nodes on the right-hand side of the graph in
the centre (2, 4) are swapped we can see that it forms the graph on the
right. Thus the graphs are the same from the structural point of view.
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structures. Triadic census and motif search are both of potentially great value when dealing
with very large graphs, since a knowledge of the types of structures that exist within a graph
can give us some idea of how it might behave on a larger scale. This was perhaps best illustrated
by Milo and Shen-Orr in 2002[56], who having applied motif search to the transcriptional regu-
latory network of E. coli showed that three motifs they had identified were of known biological
significance. Later in the same year they published a second paper, which went on to show
how the technique could also be applied to a range of other systems including food webs, the
connections between neurons in C. elegans and electronic circuits.
Since Milo and Shen-Orr’s papers in 2002, a great deal of additional work has been done in
order to speed up the search for motifs and make the technique more accessible to a range of
users. Of particular interest is the work by Berg and La¨ssig[57], which extends the idea of a
motif by introducing scoring to allow partial but not necessarily identical structures to also be
counted as part of the motif search. This could be used to take into account incomplete datasets
(often the case in large networks) and in the case of biological systems in particular, the effects
of evolution on the structure of the motif. A range of software tools for motif search exist, most
notably Mfinder[58], MAVisto[59] and FANMOD[60].
2.2.6 Metabolic pathways
Metabolic pathways are chains of reactions which when combined show how a particular function
such as the extraction of energy from food (glycolysis) or the biosynthesis of important molecules
is performed by a cell. Metabolic pathways are usually presented as graphs in which nodes rep-
resent compounds and edges represent reactions, often labeled with the enzymes that catalyse
them. The complete set of metabolic pathways for an organism is known as its metabolic
network. A number of online resources that include information on metabolic pathways ex-
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ist, of which arguably the most well-known is the Kyoto Encyclopedia of Genes and Genomes
(KEGG)[61, 62]; a suite of databases that aim to assist scientists integrating genomic and
metabolic data. The KEGG PATHWAY database (the component of KEGG that deals with
metabolic pathway information and the current basis for the Linked Metabolites software pre-
sented in chapter 5) is a collection of static “reference pathways”, that is to say that each of the
pathways contains experimentally determined reactions contributing to the process it describes
but taken from a variety of organisms and then combined to form a single graph. As many key
metabolic processes are well preserved amongst most organisms from mammals to bacteria[63] it
is possible for KEGG and other similar resources to computationally generate organism specific
pathways from the reference pathways by highlighting enzymes (and the reactions they catalyse)
in the reference pathways that are known to be present in the organism based on its annotated
genome (Figure 2.10).
MetaCyc[64, 65] is a database of reference pathways used by the BioCyc project as a base from
which to generate organism specific pathways. Unlike in KEGG, where the generated pathways
are presented as overlays to the reference pathway diagrams, the BioCyc project stores the
extracted pathways as separate databases, effectively creating whole, organism specific pathway
databases that can then be queried, edited and updated independently. When first created, the
computationally generated pathway databases have not been subject to any human curation
and may include errors or omissions; as such BioCyc has an evidence coding system to indicate
the original source of the information, be it from primary literature, computationally predicted,
predicted and then subject to curation etc. As of October 2008, over 370 computationally-derived
pathway databases were available as part of the BioCyc project, of which 20 had undergone a
limited curation effort. These included HumanCyc[66], an organism specific pathway database
for Homo sapiens.
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Figure 2.10: KEGG pathway diagrams for the TCA cycle. The top diagram
is the reference pathway and below is the same diagram highlighted based
on the annotated genome for Homo sapiens.
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While the reference pathways in databases such as KEGG and MetaCyc represent specific bio-
logical processes, the point at which a process becomes a pathway can be somewhat arbitrary,
with a single pathway in one database being represented by two or three in another. Meth-
ods exist that aim to allow the creation of organism specific metabolic pathways based on a
definition of the concept of a pathway rather than from experimentally determined reference
pathways. In 2003, Masanori Arita[67] published a method that generated possible metabolic
pathways from a graph in which edges represented a transfer of atoms between the source and
target molecules. Since creating pathways based on this type of transfer could in theory lead
to almost any molecule transforming into any other, an important concept in Arita’s work was
that there should be some degree of conservation of moiety (a structural fragment of a molecule)
along the entire length of any valid pathway, that is to say at least one atom from the source
molecule should have been passed along the pathway to the target. This is analogous to the idea
that a brush that has had two new handles and three new heads over a period of years is not the
same brush. Arita’s method contained three steps; in the first stage, just under 2,800 reference
metabolic reactions were taken from the Enzyme Nomenclature database, manually checked
against the literature for correctness (in some cases the reactions were either rearranged or bal-
anced) and then passed to a software package that mapped carbon, nitrogen and sulphur atoms
in the substrates of each of them to the equivalent atoms in their products. As was the case
with the reactions from which they were generated, the mappings were then checked by hand
and corrected where appropriate. Finally, the mappings were used to construct reference graphs
for carbon metabolism, nitrogen metabolism and sulphur metabolism, in which the nodes rep-
resented metabolites and edges represented the transfer of molecular fragments between them.
The second stage of the method involved the search for potential metabolic pathways between
source and target compounds, however for this to take place the actual metabolism of the or-
ganism of interest (in Arita’s case E. coli) needed to be selected in the reference graphs. As is
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the case in other methods using reference pathways, Arita’s method achieved this by selecting
reactions based on enzymes referenced in the annotated genome, which could be downloaded
from the KEGG database. Rather than excluding reactions that were not reported as present
in E. coli, Arita instead assigned them a much higher weighting† than those reported as present.
As a result of this, the searching of the graph for potential pathways, which was performed
using a k-shortest paths algorithm, could still report pathways that included those reactions
even though it would preferentially select those pathways that only included reported reactions.
This was important, since the annotated genome may have been either incomplete or contain
errors and thus relying on it alone could cause valid pathways to be overlooked. Any potential
pathways that looped back on themselves were rejected at this point, since while there are a
small number of genuine metabolic pathways that form loops, for example the TCA cycle (also
known as the citric acid cycle or the Krebs cycle), the vast majority of those results would be
artifacts due to the reversible nature of chemical reactions. The third and final stage of the
method involved the filtering of the potential pathways against the conservation of moiety cri-
teria discussed earlier; this involved the checking of the entire pathway against the individual
mappings in order to ensure that at least one atom from the source molecule passed along the
entire length of the path to become part of the target molecule, thus making it a valid biochem-
ical pathway. Ultimately, pathways derived in this way may prove a much more useful basis for
automated search techniques than those arranged to be easily viewed by humans and currently
available in KEGG (see chapters 5 and 6).
The computational derivation of organism specific metabolic pathways from reference pathways
has one important advantage of methods such as Arita’s; it avoids the problems associated
with compartmentalisation, the idea that only a subset of the complete genome is expressed
†When searches are performed using a shortest paths algorithm, as was the case in Arita’s work, edges with
high weights are less likely to be selected than those with low weights as they increase the length of the path.
Hence, in these cases a high edge weight is a penalty.
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in a particular tissue or cellular structure, by virtue of the experimentally determined nature
of the reference pathways. Despite this, computationally-derived databases are of limited use
because of the lack of curation (in order to remove or correct erroneous pathways) and lack
of references to evidence describing the pathway in the literature. An alternative group of
metabolic pathway databases exist that address this question by focusing on a single organism
and only containing curated data. The huge effort associated with the curation of such databases
means that they can only be created for important model organisms. A good example of this
type of database (and the database that provided much of the initial pathway information for
MetaCyc) is EcoCyc[68], a metabolic pathway database for E. coli. More recently another
curated database, Reactome[69, 70], was launched that focuses on human metabolism and then
computationally extends that effort to a small number of other important organisms. Along with
the human-specific pathway diagrams, Reactome contains citations to the literature, links to
information in external resources such as UniProt and GO, and the ability to layer experimental
results onto the diagrams. Critically, unlike other pathway databases, Reactome also includes
information on sub-cellular compartmentalisation and citations to experimental evidence for
each of its reactions; information that is vital if the database is to be used as the foundation for
in silico simulation of the pathways.
The computer simulation of metabolic pathways is an important area of research, enabling the
testing of theoretical models of metabolism against experimental results. Yet despite kinetic
modeling and simulation packages such as Gepasi[71]. E-Cell[72] and Virtual Cell[73] having
been available (in some cases) for two decades, it is only recently that the community has really
begun to embrace the field. While a component of this new-found interest is almost certainly
due to the increasing availability of low-cost, high-performance computing facilities, a large part
of the credit must also go to efforts designed to facilitate interoperability between the myriad
compound and pathway databases, the exchange of models between simulation packages and
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the reuse of existing models as components of larger systems. Amongst these two stand out,
BioPAX[74] and the Systems Biology Markup Language (SBML)[75].
BioPAX is a data exchange format for biological pathway information and is of great importance
since its ontology allows the unambiguous description of pathway objects, thus avoiding the issue
of different naming conventions across databases. BioPAX data is stored using OWL/RDF and
is therefore suitable for automated querying and combination of data from multiple sources by
web services or software agents. Most critically for any data exchange format, BioPAX has good
community support, which currently includes the BioCyc databases and Reactome.
SBML is an xml-based format for the representation of models of biochemical reaction networks,
allowing the specification of information such as reactant species, cellular compartments and
mathematical descriptions of the interactions between objects. Its aim is to provide a common
format for the exchange of such models between simulation packages thus removing the risk of
models becoming unusable if the package they were originally written in ceases to be supported,
while also making it easier for researchers to check and reuse published models that previously
may have needed to be manually recoded in the proprietary formats of multiple simulation
packages.
While metabolic pathway information in BioPAX format is available in great volume and with
unambiguously named elements allowing the easy combination of smaller pathways to form larger
ones, it does not encode all the information required for the simulation of the pathways. SBML
by comparison does contain the necessary equations and rate parameters but does not require
the unambiguous naming of elements outside the scope of an individual model. While recent
versions of SBML partially address this by allowing models to be annotated with references to
external information, the annotations are optional and SBML does not impose any restrictions
on their content. Thus, while SBML does allow models to be used in multiple simulation tools,
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it does not necessarily solve the issue of reuse of models as parts of more complex systems.
Projects such as the BioPAX modeling framework[76] are currently attempting to address this
problem by allowing fully annotated SBML models to be constructed from BioPAX data.
The methods chosen for the visualisation and exploration of metabolic pathways can have a
great impact on their usefulness, particularly if the features of interest are spread across mul-
tiple pathways. Traditionally, metabolic pathways are visualised using semi-static views like
those in KEGG, diagrams created and laid out in advance by a curator. Typically such di-
agrams cannot be edited by the end user, although they may have the facility for additional
information such as experimental results to be overlaid on them, and can only be navigated by
the use of hyperlinks, with the diagram of the linked pathway replacing that of the pathway
previously being examined. While this method can be appropriate for the visualisation of well-
defined reference pathways (particularly when there is only one pathway being investigated) it
is not at all suited to the visualisation of large systems containing multiple pathways or to the
potentially huge numbers of computationally-derived pathways. In response to this need, pack-
ages such as KGML-ED[77] have been created, which based on xml versions of the metabolic
pathways allow users to create customised, dynamic views of the pathways. These often include
the ability to customise the pathways by adding or removing elements, include multiple path-
ways in a single diagram, hide information by collapsing pathways into single nodes that can
be expanded as required, and change the layout either manually or based on standard layout
algorithms from graph theory. Many also allow the customised pathways to be exported in
formats such as SBML for visualisation elsewhere or as the basis for simulations. Packages such
as Cytoscape[78] and VisANT[79] take this a stage further by allowing the user to combine data
on metabolic pathways with gene regulation networks or by facilitating the colouring of the
on-screen network with experimental data emulating functionality previously available as part
of semi-static visualisations through tools such as those based on the KEGG EXPRESSION
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database[80], which enables the intensity ratios of spots on gene expression arrays to be mapped
onto the corresponding objects in appropriate pathway diagrams. Metabolite data has also been
visualised in-context as an overlay to the pathway diagrams, with work by Dwyer et al.[81] that
used columns of coloured blocks to represent time series concentration data being a particularly
good example. Finally, it would be inappropriate to talk about the visualisation of experimental
data in the context of metabolic pathways without mentioning VANTED[82]; a recent software
package that includes many of the techniques mentioned (combination of data from multiple
fields into pathway diagrams, flexible layouts) and combines them with analysis techniques such
as the ability to build correlation networks from experimental data.
2.2.7 Metabolic correlation networks
One of the major challenges in metabolomics is the inherent biological variability between sam-
ples, both across groups of subjects and between samples taken from the same subject at different
points in the day. Factors such as diet, the age of the subject and environmental stresses can all
lead to large variations in the metabolic profile of a sample, making direct comparisons difficult.
Fortunately, this variability also has its uses; pairwise comparisons of the levels of metabolites
across whole groups can lead to the identification of correlations within the data, indicating a
possible relationship between the metabolites in question. While heatmaps offer one method
of visualising this type of data, an alternative option is to generate a metabolic correlation
network[83], in which metabolites that are correlated more strongly than a given threshold are
linked together to produce a graphical representation of the important relationships within the
system (Figure 2.11).
The first stage in the creation of a metabolic correlation network is the assignment of correlation
values to each pair of metabolites being studied. Correlations may be calculated in a number
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Figure 2.11: Example of a metabolic correlation network.
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of ways, but the most common are the Pearson Correlation Coefficient (Equation 2.5) and the
Spearman Rank Correlation Coefficient (Equation 2.6).
r =
∑n
i=1(Xi − X¯)(Yi − Y¯ )
(n− 1)σXσY (2.5)
r = 1− 6 ·
∑n
i=1(xi − yi)2
n(n2−1)
(2.6)
The major difference between the Pearson and Spearman correlation coefficients lies in the fact
that the Pearson coefficient is parametric (there is an assumption that the data is normally
distributed) while the Spearman coefficient is not. If the data can be assumed to be normally
distributed, the Pearson correlation coefficient should be used in preference to the Spearman
correlation coefficient. They also differ due to the ranking approach used by the Spearman
correlation coefficient. In the Pearson coefficient, the correlations are calculated based on the
distance between equivalent points in the data series being used. The Spearman correlation
coefficient however, uses the distance between the ranked order of the equivalent points, meaning
that data series that are identical in shape but differing in average amplitude will appear more
highly correlated than they would using the Pearson correlation coefficient. The Spearman
correlation coefficient will also return a more favourable result in situations where the data
contains a relatively small number of outliers, as the difference in the rankings will be small
compared to the actual difference between the values of those points.
The strength of a correlation is not necessarily proof of its significance, which is affected by
factors such as the size of the underlying dataset. As such before a metabolic correlation
network can be constructed a p value (measure of significance) must be calculated for each r
value (strength of correlation). Correlations that result in a p value of less than 0.05 are normally
considered to be significant, although this value should really be adjusted to reflect the number of
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correlations being calculated through the use of Bonferroni corrections, false discovery rates[84]
or similar. The conversion of r to p values can be performed either by reference to standard
tables, or through the use of t-tests. Since t-tests require the assumption that the samples within
the dataset are normally distributed, metabolic correlation networks should not be constructed
from datasets with fewer than 20-30 samples.
Once p values have been determined for all pairs of metabolites under investigation, the con-
struction of the network becomes a simple task. Every metabolite is represented in the network
by a node. Next, the correlation value for each pair of metabolites is considered; if the signifi-
cance (p value) for that correlation is below the threshold value determined previously then an
edge is added to the network between the correlated metabolites. Commonly, the weighting of
the new edge is then set to the strength (r value) of the correlation it represents.
For an example of the use of metabolic correlation networks in the investigation of tumours in
dab liver samples, see chapter 4.
2.2.8 Time-series methods for biochemical network discovery
While metabolic correlation networks can be a useful tool for the exploration of experimental
data, the difficulties associated with relating interesting features in the networks to the un-
derlying biochemistry mean that the results of such analyses can at best only be considered
indicative. There are however, a set of methods that allow the direct reconstruction of networks
of biochemical reactions from time-series data of simple systems. Although the type of data
required for this process‡ means that such approaches are currently of limited applicability to
‡When not being driven by external factors such as changes in temperature or the lack of availability of required
‘input’ compounds, systems of chemical reactions will tend to settle into a steady state where each of the reactions
proceeds at a constant rate and the concentrations of the compounds involved are effectively fixed. The network
reconstruction methods discussed here require the perturbation of the system away from this state and as such
can only really be used on data gathered in vitro.
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metabolomics, a summary of them is included in appendix A as an interesting future alternative
to the use of metabolic correlation networks and reference pathways.
2.3 Summary
This chapter has introduced the key concepts that will be used in this thesis. It began with
a description of metabolomics, the study of the low molecular weight compounds involved in
metabolic processes, and went on to give examples of its applications in environmental toxicology
and healthcare. The following sections discussed graph theory, introducing a number of different
types of graph and metrics that could be used to distinguish between them, before showing how
the structure of a graph can give insights about the system that it is modeling. Finally, it
brought the two topics together, showing how biologists have chosen to represent their current
knowledge of metabolism in a series of graphs known as the metabolic pathway diagrams, how
they are attempting to explore their experimental datasets using metabolic correlation networks,
and mentioning how they might reconstruct networks of biochemical reactions from experimental
datasets in the future. The next chapter will go on to discuss some of the limitations of the
current approaches, and ask what might be done to address them.
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CHAPTER 3
LIMITATIONS OF CURRENT APPROACHES
3.1 Metabolomics and the identification of biomarkers
Although a comparatively recent addition to the -omics family, metabolomics with its low per-
sample cost and good portability across species (when compared to other -omics technologies),
has huge potential both as a standalone analytical technique and as a component of larger
integrated genomics studies. In particular, two key features of the technology, the fact that it
focuses on the low-level molecular processes of the cell and its ability to be used non-invasively
through MRS or on biofluids such as urine, make it an ideal tool for screening work in areas
such as medicine or environmental toxicology.
Unfortunately, many of the factors that contribute to the strengths of metabolomics within
these fields are also its greatest weaknesses. The biological variation between subjects due to
age and sex, local environmental conditions and dietary differences are all reflected in the results
of a metabolomics experiment and often make the data noisy and difficult to use. While it is
sometimes possible to reduce the impact of these effects on the data, through the use of careful
experimental design, this is often undesirable as the control measures themselves may mask
interesting features in the data or add to the risk of any discoveries that are made only being
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applicable in a narrow range of experimental conditions, greatly limiting their more general
usefulness. The experimental difficulties will however be reduced as the technology matures,
and ultimately it will be the ease of interpretation of the data that determines how widely and
in which fields metabolomics is adopted.
Since it is highly unlikely that the concentration of a single compound alone will uniquely iden-
tify and determine the extent of a particular condition, current methods for the identification
of biomarkers centre on multivariate statistical tools such as Principal Components Analysis
(PCA). These techniques, when used in conjunction with significance tests, will often identify
an extensive list of compounds that in some way contribute to the differences between the sam-
ples in a study. Many of these will be “usual suspects”; compounds that are involved in processes
related to, but not the root cause of, the condition being studied such as apoptosis (cell death)
or anaerobic respiration. The inclusion of such compounds in a list of biomarkers would lead
to highly complex identification rules for the condition - rules that would be cumbersome to
implement, difficult to extend as further data became available, and most importantly consider-
ing the essentially safety-critical nature of many of the applications∗, impossible to explain and
validate.
Thus, within every metabolomics study a careful balancing act must be performed. The set
of biomarkers for a condition needs to be complex and resilient enough to specifically identify
that condition despite experimental noise and biological variation, simple enough that it can
be easily applied by practitioners in the field, and only contain compounds that have a clear
and understandable biological rationale for their inclusion. At the heart of this problem is the
ability to relate trends observed in the experimental data, to the well-characterised biochemical
∗In this case, the safety-critical component is due not to a risk to the subject posed by the use of metabolomics
itself (which owing to its potential for non-invasive use actually carries a lower risk of damage to the subject than
current methods such as biopsy), but to the potential for problems that would result in the case of false-negative
results, where diseases or toxic effects were allowed to continue untreated.
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processes that make up the metabolic pathways.
3.2 Relating experimental data to biological processes
The generation of a mapping between experimental data and the metabolic pathways is far
from being a trivial task. It could be argued that to date the most effective approaches have
also been the most straightforward; those that layer experimental data onto pathway diagrams.
These techniques, initially driven by work such as that of Dwyer[81] and available as part of tools
like VANTED[82], prove most useful when the set of metabolites being studied is taken from
either a single or a small number of pathways, allowing the researcher to judge the relationship
between the metabolites by eye. They are also particularly effective when used with time-series
data, allowing changes in concentrations to be traced through the pathways. However, studies
focused on a single pathway are far from the norm and the large number of pathways stored
in databases like KEGG can make comparison by eye alone a slow and difficult task. This
problem is compounded by the relatively low-resolution of the technology as it currently stands;
a difficulty that is particularly evident in the case of MRS where the number of metabolites that
can be observed is presently only a small fraction of that for in-vitro methods. This low coverage
of the metabolome means that it is highly unlikely that the set of metabolites being observed
in an experiment will naturally fall in close proximity to one another within a single metabolic
pathway diagram. Instead, they are likely to be spread over several different pathways, making
it difficult to form coherent chains of reactions that link the compounds together.
Correlation analyses can be very helpful when interpreting metabolomic data, as they can be used
to indicate how compounds might be related before the time-consuming process of searching the
known metabolic pathways takes place. However, difficulties do exist with this approach; firstly
the existence of a correlation between two metabolites is not in any way proof that it is significant.
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While a number of methods for determining the significance of a correlation exist, including both
Bonferroni and false discovery rate-corrected p values from t tests, the choice of method and
of threshold value still has a very noticeable effect on the selection of correlations, an effect
that is undesirable when trying to establish a common basis for further research. Secondly, we
have the issue of “long-range” effects; just because a correlation exists between two metabolites
there is not necessarily an obvious link between them in the underlying biochemistry, as Steuer,
Kurths, Fiehn and Weckwerth remarked “...there is no straightforward connection between the
observed correlations and the underlying reaction network. We observe strong correlations
between seemingly distant metabolites, whereas metabolites sharing a common reaction are
not necessarily correlated.”[85]. Still, while the combination of correlation analyses and the
metabolic pathway diagrams may be a far from perfect way of determining how experimental
results can be explained in terms of the underlying biochemistry, they are considerably more
practical (given current experimental limitations) than more advanced methods such as those
based on the reconstruction of the metabolic network from time-series data.
Since a correlation analysis of even a small system produces a reasonably large number of results
(a correlation analysis of time-series data of 4 metabolites results in 6 correlations assuming
you ignore correlations of a compound to itself), the method chosen for the visualisation is
important. Correlations are normally viewed as heatmaps, however an interesting alternative
is the metabolic correlation network (Section 2.2.7) as proposed by Steuer et al.[85]. Metabolic
correlation networks offer possibilities to further automate the process of relating experimental
data to the metabolic pathways since they are essentially in the same form, graphs.
The categorisation of graph structure has been developed greatly over the past 50 years, mainly
due to the interest of sociologists, and a wide range of metrics have been devised to determine the
types of properties a graph may have based on its structure. Of these, motif search (Section 2.2.5)
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stands out as a particularly good example, showing how repeated structural features within the
network may be related to important functions within the system it represents. The expected
types of structure within the network being studied do of course impact heavily on the metrics
that should be used. In the case of locating a set of reactions that correspond to a correlation
for example, one sensible approach might be to study the betweenness centrality values of
metabolic pathways that link the compounds involved in the correlation. High betweenness
centrality would suggest that a large proportion of the routes involve that step and therefore
that it is likely to be involved in the observed correlation.
To assume that such simple rules of thumb could be made to solve all the issues involved in
this problem would however be a gross under-estimation, as the way a correlation appears can
depend on a large number of factors. As an example, consider a short section of the glycolysis
pathway (Figure 3.1(a)) in which circles represent metabolites, arrows represent reactions, and
the numbered boxes represent enzymes. To begin with, assume that there is a metabolomics
dataset that has concentrations for glycerate 3-phosphate (glycerate-3P) and phosphoenolpyru-
vate. In glycolysis glycerate-3P is turned into phosphoenolpyruvate so we’d expect that these
two compounds would be correlated (Figure 3.1(b)). Now assume that our dataset has been ex-
panded to include glycerate 2-phosphate (glycerate-2P), since glycerate-3P forms glycerate-2P
and glycerate-2P then goes on to form phosphoenolpyruvate we might expect the correlation
network to look much like the pathway (Figure 3.1(c)); however, correlation networks are not
like pathway diagrams, glycerate-3P and phosphoenolpyruvate will still be correlated, despite
not being directly connected in the pathway (Figure 3.1(d)). This is an example of how the
experimental ‘coverage’ of the compounds can drastically alter the appearance of the correlation
network compared to the metabolic pathway it represents; a small number of relatively distant
compounds may look quite similar to the pathway (although there is of course a risk that some
other factor might mean they are no longer correlated), whereas compounds that are close to-
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Glycerate-3P
Phosphoenol-
pyruvate
(b)
Glycerate-3P
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Phosphoenol-
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(c)
Glycerate-3P
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(d)
Glycerate-3P
Glycerate-2P
Phosphoenol-
pyruvate
(e)
Figure 3.1: A small section of the glycolysis pathway shown with several
possible metabolic correlation networks.
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gether will tend to form cross-connected groups. To further complicate this situation, while the
metabolic pathways are drawn to represent particular processes in an easily interpretable form,
many pathways are at work within a single cell at any one time forming a much larger, intercon-
nected system. The dotted arrow coming into the pathway (Figure 3.1(a)) from the right hand
side is KEGG’s way of showing that glycerate-2P can also be formed in another pathway (in
this case the pentose phosphate pathway) and feed into glycolysis at that point. If in the other
pathway glycerate-2P is formed from a compound other than glycerate-3P, and the rate of flow
of glycerate-2P into glycolysis from the other pathway is faster than the rate of formation from
glycerate-3P, then the correlation between glycerate-3P and glycerate-2P may not be significant
(Figure 3.1(e)). The correlation network does not of course, contain any information on our ar-
tificial partitioning of the metabolic system; however, when looking at it you could be forgiven
for thinking that the glycolysis pathway is not involved in the process the network represents,
when actually it may be important but just flowing at a low rate.
Thus, while correlation networks can be used to represent experimental data in a form that is
comparable to the metabolic pathways, issues of “coverage” of the pathways by the experimental
data, the completeness in terms of the underlying metabolism of the metabolic pathways them-
selves, and the current dynamic state of the metabolic networks within the subjects (the rates of
flow through various parts of the pathways as determined by enzyme activity, temperature etc),
mean that there is currently no straightforward way of automatically aligning the two. Indeed,
the question of network dynamics is as of yet largely untouched and while likely form the major
area of research for the graph theory community over the next decade.
Given the lack of a suitable framework for the development of a completely automated solution
to this problem, we are left with attempting to facilitate current manual efforts. Many of the
current approaches involve selecting compounds from the lists generated by statistical tests
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that all feature in the same pathways, and then investigating the links between them by eye.
Alternatively tools such as KEGG PathComp might be used to link them automatically, but this
is usually limited to either a single-source to multiple-targets, or multiple-sources to single-target
search.
Here, we will investigate how metabolic correlation networks can be used to identify sets of
related metabolites which seem to contribute to the differences between the sample groups. We
will then look at how an all simple paths search algorithm can be used to perform multiple-
source, multiple-target searches, creating a directed metabolic graph, which can be used to
visualise the relationship between the compounds groups in terms of the biochemistry.
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CHAPTER 4
METABOLIC CORRELATION NETWORKS OF LIVER
TUMOURS IN DAB
4.1 Background
One of the greatest strengths of metabolomics as an analysis technique lies in the ability of
the metabolome to quickly reflect the effects of changes in the environment. Unfortunately
this means that the data gathered is often very noisy, due not only to biological variation but
also factors such as diet, age and time of day, along with those being studied. In situations
where sufficiently large numbers of subjects are available, using correlations between metabolite
concentrations can help overcome this problem. Unfortunately, even a relatively small dataset
of 30 metabolites will result in over 400 separate correlations∗, leaving the researcher facing
what is still a highly complex analysis task. This chapter aims to show how using metabolic
correlation networks (Section 2.2.7) to present the data in a manner that is easily interpretable
by eye can help researchers identify features in their data, which they can then use as the basis
for further research such as searches of the metabolic pathway diagrams.
∗Assuming the correlation between A & B is the same as the correlation between B & A, the number of unique
correlations is given by n
2−n
2
where n is the number of metabolites.
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4.2 Initial investigation (2005 analysis)
4.2.1 Method
Metabolic correlation networks were constructed from NMR metabolomics data of 20 samples
taken from dab, a common flatfish. Flatfish are frequently used in environmental monitoring
work, since they live in close proximity to the ocean floor and are therefore exposed to the
chemicals that accumulate there. Of the 20 samples, which were taken from a total of 10 fish,
10 were samples of tumour tissue (one per fish) and the remaining 10 were matched samples
of normal liver tissue taken from the same 10 fish. Analysis of the NMR data led to the
identification of 33 separate metabolites, each of which was then quantified. All data collection
and metabolite quantification work was performed by metabolomics practitioners within the
School of Biosciences. The samples were then analysed as three groups; normal tissue, tumour
tissue, and a third group in which both the normal and tumour tissue samples were treated as
a single, combined dataset. In each case, a series of networks was produced with cut-off values
for the inclusion of a correlation into the network ranging from ± 0.1 to ± 0.9. The Pearson
correlation coefficient was used to generate correlation values for all pairs of metabolites within
the groups. Positive correlations were represented in the networks by solid lines, while dashed
lines were used to represent negative correlations. The calculations were performed using R[86],
a free software environment for statistical computing that is widely used within the biological
community.
While the metabolic correlation networks do summarise a large amount of information effectively,
they can still be difficult to compare by eye. In order to highlight the differences between the
groups and thereby ease the task of analysis, the intersection between the normal and tumour
tissue networks was taken for each threshold value and subtracted from both of the networks.
59
Calculate Pearson 
correlation coefficients 
for each pair of 
metabolites
Compile correlation 
network for each 
threshold value
Perform network 
intersections to produce 
networks of correlations 
present in normal tissue 
only, tumour tissue only, 
and in both normal and 
tumour tissue
Assign and quantify 
metabolites in raw data
Figure 4.1: Process used for the generation of the metabolic correlation
networks in the 2005 analysis.
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This had two effects, firstly two new series of metabolic correlation networks were created that
contained only those correlations which appeared in either the normal tissue network or the
tumour tissue network at that threshold value. Secondly, the intersections themselves could be
used as a third new series of networks, which showed those correlations common to the normal
and tumour tissue networks. The key steps in the method are summarised in figure 4.1. The
networks were manipulated and visualised using Pajek[87], a program originally designed for the
analysis of social networks (Figures 4.2 to 4.11).
4.2.2 Results
The networks showing the correlations present in the normal tissue samples but absent in the
tumours (Figures 4.5, 4.6 and 4.7) indicate that there are strong positive correlations between
fumarate and leucine, and fumarate and isoleucine (Figure 4.6). A positive correlation usually
indicates that one of the metabolites in involved either directly or indirectly in the formation
of the other. In this case the valine, leucine and isoleucine degradation pathway feeds into the
TCA cycle just upstream of fumarate (although both leucine and isoleucine can also feed in
at an alternative point further round the cycle). The presence of these correlations in normal
tissue but not in the tumour tissue suggests therefore that there may be an alteration to the
activity of that section of the TCA cycle within the tumour tissue. The presence of additional,
weaker positive correlations between isoleucine and malate, fumarate and valine, and malate
and valine (Figure 4.7), when malate is also involved in the TCA cycle immediately downstream
of fumarate also appear to support this hypothesis. In contrast to this, the correlation between
fumarate and malate appears in both normal and tumour tissue (although at slightly higher
strength in the tumour tissue) suggesting that this step remains largely unaltered, possibly due
to one of the alternative pathways that can feed fumarate into the system (Figure 4.12).
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Figure 4.2: Metabolic correlation networks from dab liver samples. Normal
tissue group. Thresholds from±0.1 (top left) to±0.9 (bottom). Data taken
from the 2005 analysis.
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Figure 4.3: Metabolic correlation networks from dab liver samples. Tumour
tissue group. Thresholds from±0.1 (top left) to±0.9 (bottom). Data taken
from the 2005 analysis.
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Figure 4.4: Metabolic correlation networks from dab liver samples. Normal
and tumour tissue combined group. Thresholds from ±0.1 (top left) to±0.9
(bottom). Data taken from the 2005 analysis.
64
Figure 4.5: Metabolic correlation networks from dab liver samples. Cor-
relations present only in normal tissue group. Thresholds from ±0.1 (top
left) to ±0.9 (bottom). Data taken from the 2005 analysis.
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Figure 4.6: Metabolic correlation networks from dab liver samples. Corre-
lations present only in normal tissue group. Threshold of ±0.9. Data taken
from the 2005 analysis.
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Figure 4.7: Metabolic correlation networks from dab liver samples. Corre-
lations present only in normal tissue group. Threshold of ±0.8. Data taken
from the 2005 analysis.
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Figure 4.8: Metabolic correlation networks from dab liver samples. Cor-
relations present only in tumour tissue group. Thresholds from ±0.1 (top
left) to ±0.9 (bottom). Data taken from the 2005 analysis.
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Figure 4.9: Metabolic correlation networks from dab liver samples. Corre-
lations present only in tumour tissue group. Threshold of ±0.9. Data taken
from the 2005 analysis.
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Figure 4.10: Metabolic correlation networks from dab liver samples. Cor-
relations present only in tumour tissue group. Threshold of ±0.8. Data
taken from the 2005 analysis.
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The networks showing the correlations present in the tumour tissue samples but absent in the
normals (Figures 4.8, 4.9 and 4.10) show a high negative correlation between alanine and formate,
and alanine and acetate(Figure 4.9). This is interesting as the US National Cancer Institute say
that a high level of the enzyme alanine transferase may be a sign of liver damage, cancer and
other diseases [88]. It is also known that under fasting conditions, alanine, derived from protein
breakdown, can be converted into pyruvate and used to synthesise glucose in the liver via the
gluconeogenic pathway[89]. Since it is common for tumours to rapidly outgrow the sources of
oxygen and nutrients available to them (leading to necrosis in the centre of the tumour) it would
not be surprising for tumour tissue to behave in a way which resembled fasting, hence altering
alanine metabolism within the sample. An apparently strong correlation between fumarate
and malate can also be seen in the tumour tissue at the ± 0.9 threshold(Figure 4.9), although
looking back at the ± 0.8 threshold level it no longer appears (Figure 4.10). This suggests that
the correlation is not a result of a major difference in metabolism within the tumour tissue, but
is instead due to a slight alteration in the strength of the correlation between the normal and
tumour tissue sample groups that occurs near the threshold.
4.3 Detailed investigation (2008 analysis)
4.3.1 Method
The data from the dab samples was recently reanalysed prior to publication in the Journal of
Proteome Research[90], resulting in the identification of two additional metabolites. Pearson,
Spearman and Kendall correlation coefficients were all calculated for the normal and tumour
tissue groups, although only the results of the Pearson correlations were used in the paper. The
thresholding approach used in the previous analysis was rejected in favour of a more formal
method, which used p values and a false discovery rate[84] less than 10% for the calculation
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Figure 4.11: Metabolic correlation networks from dab liver samples. Cor-
relations present in both the normal tissue group and the tumour tissue
group. Thresholds from ±0.1 (top left) to ±0.9 (bottom). Data taken
from the 2005 analysis.
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Figure 4.12: A section of the KEGG metabolic pathway diagram for the
TCA cycle. The green arrows indicate the points at which the valine, leucine
and isoleucine degradation pathway feeds into the cycle. The red arrow
shows the direction of the dominant flow around the cycle. fumarate and
malate are shown in blue.
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of significance and hence inclusion in the networks. Two metabolic correlation networks, one
for normal and one for tumour tissue were produced and these were manually inspected for
differences. The key steps in the method are summarised in figure 4.13.
4.3.2 Results
The 2008 analysis was performed by an expert biologist and the results are included here to
allow a comparison to be made with the results of the 2005 analysis. A total of 33 significant
correlations were noticed in two groups. Of these, fumarate was involved in seven correlations
and six of those were present only in the healthy tissue. Several significant correlations involving
acetate were seen in the tumour tissue samples, as were correlations involving alanine, succinate,
and NAD+. All of these were interpreted as being indicative of a switch from aerobic to anaerobic
metabolism in the tumour tissue due, at least initially, to the tumour outgrowing its oxygen
supply; it is also thought however, that many of the metabolic processes involved in anaerobic
metabolism may be beneficial to the growth of tumour cells. One result of a switch to anaerobic
metabolism would be a reduction in the amount of NAD+, normally produced by oxidative
phosphorylation in the mitochondria. NAD+ is required for the generation of ATP by glycolysis
and is hence vital to the function of cells. The production of NAD+ normally takes place as
part of the TCA cycle, and a slowing of its production and feeding into the electron transport
chain would also impact on the formation of FADH2 during the succinate to fumarate step of the
cycle. This would be in line with the number of altered correlations in that region of the cycle
noted in the previous analysis. An alternative mechanism for the production of NAD+ involves
the conversion of alanine to pyruvate and then to lactate, producing NAD+ as a byproduct.
This would explain the correlations involving alanine seen in the tumour tissue, and again, is
consistent with the findings of the previous analysis. A slowing of the TCA cycle would also cause
a buildup of compounds that feed into it such as acetyl CoA, this could be broken down by an
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Figure 4.13: Process used for the generation of the metabolic correlation
networks in the 2008 analysis.
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alternative mechanism forming acetate, explaining the correlations involving it and compounds
such as alanine that can form pyruvate and then acetyl CoA.
A set of findings of the 2008 analysis that were not noticed in the earlier analysis involve
choline metabolism. The alteration of choline metabolism, a process that can create a compound
(S-adenosyl-L-methionine) which regulates gene expression, might lead to the expression of
unwanted genes including those involved in the development of cancers. While these correlations
were present in the networks built during the previous analysis, the difficulties associated with
deciding which thresholds to use meant they were missed. This is a strong endorsement of the
more formal thresholding approach used in the more recent analysis.
4.4 Conclusions
While metabolic correlation networks offer little additional information than the correlations
themselves they are certainly easier to interpret by eye, highlighting features and interrelation-
ships that might otherwise be missed. As the issue of choline metabolism in this work has
illustrated, the selection of thresholds is vital to the construction of a meaningful network; too
low a threshold value and non-significant results are included making it difficult to see impor-
tant features, too high and information is lost. As such, selecting an appropriate thresholding
approach such as p values combined with Bonferroni corrections or a false discovery rate is of
great importance to the success of a metabolic correlation network based analysis.
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CHAPTER 5
THE DISCOVERY OF LINKS BETWEEN GROUPS OF
COMPOUNDS WITHIN THE KEGG PATHWAY
DIAGRAMS
5.1 Background
Multi-dimensional analysis techniques such as PCA will often, when combined with statistical
significance tests and applied to complex datasets, identify multiple compounds that may be
used to differentiate between groups of samples within the data. However, identifying these com-
pounds is frequently only part of the battle as the much more difficult task involves establishing
why they seem to contribute to the difference between the samples, placing that information in
a biological context, and determining what, if anything, their ability to distinguish between the
groups can tell us about the diseases or conditions that define them.
One way in which this problem can be tackled is through the identification of routes (chains of
reactions and intermediary compounds) linking the compounds of interest within the metabolic
pathways. Since a large number of routes can exist between two compounds, particularly if the
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search is allowed to span multiple pathways, many of the major metabolic pathway databases
provide tools that allow this process to be performed quickly and efficiently. By carefully ex-
amining the routes produced it is possible to identify reactions, enzymes and compounds that
may also be involved in the process under investigation; these can then be used either in the
validation of the compounds as biomarkers for the disease or condition being studied (by the
prediction of their behaviour and comparison of this to experimental results) or as the basis for
further research. By combining the routes between a pair of compounds (Figure 5.1) it is possi-
ble to produce a network that in this document will be referred to as a directed metabolic graph;
this is in order to draw a distinction between it and other types of metabolic networks such as
the metabolic pathways or metabolic correlation networks. The combination of the individual
routes into a directed metabolic graph has the advantage of allowing graph theory metrics for
the determination of key structural features, such as betweenness centrality or motif search, to
be applied to the data. These can be used to efficiently identify features such as reactions that
are common to a number of routes, which may not be immediately apparent from the routes
when considered in isolation (Figure 5.2). By extending the initial route search to allow either
a group of source compounds or a group of target compounds, several of the available database
search tools increase the amount of information in the directed metabolic graph; despite this
the full potential of the technique is not realised, as no tool currently provides multiple source
to multiple target searches and therefore the complete set of routes between all the compounds
is not available in a single graph.
Thus, there is a need within the community for a tool that can take two groups of compounds,
find routes between them through the metabolic pathways, and present the results both in the
context of the pathway diagrams and as directed metabolic graphs suitable for further analysis
using graph theoretical techniques.
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Figure 5.1: A section of the KEGG pathway diagram for methionine
metabolism (top). Two routes exist between L-homocysteine and S-methyl-
5’-thioadenosine (bottom left, bottom centre), which can be combined to
form a directed metabolic graph (bottom right). Since in this example the
routes are taken from a single pathway, the directed metabolic graph looks
very similar to the metabolic pathway from which it was derived. How-
ever, in situations where additional pathways or compounds are included
the graph will become too complex for easy manual interpretation and met-
rics that can summarise the structure will be required for analysis.
79
Figure 5.2: A directed metabolic graph with betweenness centrality val-
ues giving an indication of how the shortest paths through the graph are
distributed
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5.2 Method
Linked Metabolites, a graphical tool (Figure 5.3) written in Python was produced that creates
directed metabolic graphs for two groups of compounds based on the KEGG pathway database.
Python, which is an interpreted rather than a compiled language and therefore not known for its
speed, may not seem the obvious choice for this type of application. There were, however, several
good reasons for its selection. Firstly, Python is cross-platform making it easy to circulate the
code. This was important as although the application was not originally intended for release
to the community, different members of the group work with a range of operating systems
and supporting them all in a compiled language such as C would have been time consuming.
Python also offered significant benefits when used for rapid prototyping; its ease of use and
clear syntax, which are comparable to those of a scripting language, coupled with its support for
object-oriented programing, allowed quite major changes to be made to the code in a relatively
short time. Most critically, Python is based on C. Thus while Python itself is not particularly
fast, natively compiled, third-party libraries written in C/C++ could be used for many of the
important processing steps, greatly reducing the runtime. Of these, the most important was
the Boost Graph Library[91], which contains fast implementations of a number of key graph
algorithms including shortest paths, depth- and breadth-first searches, and checks for connected
components.
The KEGG database was chosen for use in the tool as its diagrams of reference metabolic
pathways allowed for the possibility that multi-species support may have needed to be added
to the code at a later date. Unfortunately, it also meant that several compromises had to be
struck. The KEGG database contains far more than just information on the metabolic pathways,
including information on compounds, enzymes, and a number of annotated genomes. As a result,
it would be impractical to expect every end-user to install complete, local copies of KEGG for
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Figure 5.3: The graphical user interface of Linked Metabolites displaying
a directed metabolic graph.
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use with the tool. Fortunately, a SOAP web service is provided to allow developers to get around
this problem, and is used by Linked Metabolites to obtain pathway diagrams, but the volume
of data needed to perform the searches themselves was far too great to allow this type of access.
As a result, Linked Metabolites relies on both the KEGG’s web service and a locally-stored copy
of the xml files for the pathways, plus definitions for the appropriate compounds and reactions.
While this solution provides an acceptable balance between installed size and speed/runtime for
the searches, it also generates several problems; Linked Metabolites must have a connection to
the internet in order to function, the locally-stored information can quite rapidly fall behind the
current version of KEGG being used by the web service forcing time-consuming updates, and
debugging becomes very difficult as each user has a subtlety different version of the database
(dependent on the time they last updated the stored files). Implementing the tool as a web
service would have removed many of these issues as there would have been only one installation
to update, however the processor and memory intensive nature of the searches and a lack of
resources made this impractical at the time of coding.
Linked Metabolites constructs directed metabolic graphs in three stages. In the pre-processing
stage potentially relevant information is extracted from the XML representations of the metabolic
pathways for Homo sapiens and compiled into a series of temporary graphs, one for each path-
way. The second stage of the algorithm involves the searching of those graphs for routes between
pairs of compounds as selected from the source and target groups specified by the user. Finally,
the post-processing stage combines the routes identified into directed metabolic graphs of vary-
ing forms; from a single source to a single target, from a single source to multiple targets, from
multiple sources to a single target, and from multiple sources to multiple targets.
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5.2.1 Pre-processing
The pre-processing stage of the algorithm (Figure 5.4) is concerned with the construction of the
directed graphs on which the route searches will be performed from a user-defined subset of
the XML representations of the KEGG pathway diagrams. Within a graph each compound is
featured as a single node, regardless of the number of occurrences of that compound within the
pathway diagrams themselves. Arcs linking the nodes are created based on substrate to product
relationships between compounds in relevant reactions. Parallel arcs between compounds are
permitted and occur if two compounds share a substrate to product relationship in multiple
reactions. If the route search is to be performed within individual pathways a separate graph
is created for each pathway, whereas if the search is to be performed across a set of pathways
a single, combined graph is used. The graphs produced by this stage of the algorithm will
henceforth be referred to as the “base graphs”.
5.2.2 Route search
Once the base graphs have been compiled, the algorithm enters its second stage (Figure 5.5). A
pre-search is performed on each base graph to ensure that at least one member of each compound
group features within it. Pairwise searches are then performed using an algorithm devised by
Rubin[92] to identify all the simple paths (where a simple path is a route in which each node
can feature only once) between members of the two compound groups. Since the algorithm is
O
(
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it is important to reduce the size of the graph on which the search is performed as far as
is possible, as such a cut-down graph for each of the pairwise searches is constructed from the
appropriate base graph. The cut-down graph features only those nodes from the base graph for
which the sum of the shortest path from the source node to the node of interest (calculated as a
single step for each cut-down graph using the Bellman-Ford all shortest paths algorithm[93, 94])
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Figure 5.4: Flowchart showing the pre-processing stage of the algorithm.
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and the shortest path from the node of interest to the target (calculated individually for each
node using Dijkstra’s algorithm[95]) is within the maximum number of steps specified by the
user. This filtering stage is safe, as if the shortest route from source to target via the node
of interest is not within the maximum length, no simple paths of appropriate length will pass
through the node. It should however be noted that inclusion at this point does not imply that all
routes through a node will be valid, as many may be over-length. Since Rubin’s algorithm does
not support parallel arcs, only one arc (in each direction if appropriate) is included between
compounds in the cut-down graph. Once the paths have been identified the arcs are then
expanded recursively using the appropriate base graph in order to obtain the complete set of
simple paths featuring all the possible combinations of reactions. Finally, any remaining routes
that are longer than the maximum length are filtered out.
It should be noted that while a compound can feature in both the source and target groups,
the algorithm will not search for routes between a compound and itself (as this would not be a
simple path). Such paths may, however, appear in the results if a route with a compound as its
source intersects with another route in the graph for which that same compound is a target.
5.2.3 Compilation and presentation of routes and directed metabolic graphs
In the final stage of the algorithm (Figure 5.6) the simple paths identified during the route search
are returned to the user in several forms; as generic routes, in which objects (compounds or the
reactions that link them) are not placed in any specific context, as pathway-specific routes, in
which every object in the route is assigned to a particular pathway, and as directed metabolic
graphs, which are combinations of the generic routes. While the first two forms can already be
obtained via the KEGG PathComp tool, their identification is a necessary step in the generation
of the networks and so it is appropriate to include them here.
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Figure 5.6: Flowchart showing the post-processing stage of the algorithm.
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Generic routes
The generic routes are the raw results of the route search, comprising chains of compounds
and reactions with no additional contextual information. In many ways the generic routes are
more useful than the more complicated pathway-specific routes that are generated from them,
as they allow the user to easily see how many non-identical paths exist between the source and
target compounds; a task that often becomes far more complex when considering routes that
are effectively identical but are being presented from the point of view of a different metabolic
pathway.
Pathway-specific routes
The pathway-specific routes are generated from the generic routes by the recursive expansion
of each of the objects in a route according to the pathways in which it features. As any given
reaction can occur in a number of different pathways, this process can result in a large number
of pathway-specific routes being generated from each of the generic routes. Once identified (and
before it is presented to the user), each of the pathway-specific routes is ranked based on the
minimisation of a heuristic function:
Score = (
n∏
p=1
sr
sp
)× n− n
sr
(5.1)
Where n is the number of metabolic pathways referred to by the route, sp is the number of steps
in metabolic pathway p, and sr is the total number of steps in the route. The ranking is designed
to promote shorter routes within a single pathway, routes involving small numbers of pathways
or routes where the steps in the route are evenly distributed across the pathways involved, over
those that feature larger numbers of steps spread over multiple pathway diagrams. The ranked
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pathway-specific routes are then presented to the user both as textual descriptions and coloured
pathway diagrams obtained via the KEGG API.
Directed metabolic graphs
Directed metabolic graphs are generated from the generic routes based on the combination of
compounds in the user-specified groups as previously discussed; single source to single target,
multiple sources to single target, single source to multiple targets and multiple sources to multiple
targets. The construction of the graphs themselves is a trivial process, purely a case of merging
the appropriate generic routes. The directed metabolic graphs are returned to the user as images,
in which compounds that are the source of routes are coloured green, targets are coloured red,
and those compounds that are both sources and targets are yellow∗. The remaining compounds
are coloured blue. Graph layouts are calculated using the GEM algorithm[96].
Combined, the three stages form the complete algorithm (Figure 5.7).
5.3 Results
5.3.1 Comparison with KEGG PathComp
In order to obtain an estimate of the coverage of the tool, routes searches were performed
between a series of compound pairs selected at random from the first one hundred compound
codes in the KEGG database. It was necessary to use pairs of compounds as opposed to groups
because KEGG PathComp, the tool against which the results were compared does not support
searches between groups of compounds. Of the 200 compound pairs initially generated, 45
were rejected because they included a compound that did not feature in any of the metabolic
∗In order to be coloured yellow a compound must be acting as a source and a target for routes in the graph,
not just feature in both the user-specified source and target groups.
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Figure 5.7: Flowchart showing the complete algorithm used by Linked
Metabolites.
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pathways. Each of the remaining 155 pairs was then randomly assigned a maximum path length
of between four and eight steps. Searches for routes (up to the assigned length) between each
compound pair were then performed using Linked Metabolites and KEGG PathComp and the
results summarised (Table 5.1, Figure 5.8).
Overall, Linked Metabolites found nearly twice as many routes between the 155 compound
pairs as KEGG PathComp, although PathComp found routes between a higher proportion of
pairs. In those cases where PathComp outperformed Linked Metabolites the cause was usually
that PathComp was finding routes via compounds or reactions that were not included in the
metabolic pathways and were, therefore, unavailable to Linked Metabolites when its searches
were performed.
KEGG Linked
PathComp Metabolites
Total number of routes found 628 1152
Percentage of pairs for which routes were found 29.7 19.4
Average number of routes per pair 4.1 7.4
Table 5.1: Summary of the results of the random route searches.
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Figure 5.8: Comparison between Linked Metabolites and KEGG PathComp
of average number of paths found per compound pair.
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5.3.2 Example usage: Investigation of the biology underpinning a set of ratios used to
differentiate between tumour types
In a study by Harris et al.[25] the ratios between the heights of peaks due to four metabolites
in short-echo-time, single-voxel MRS spectra were used to differentiate between three types of
childhood cerebellar tumour. Here we will use Linked Metabolites to investigate the relationships
between those compounds in the metabolic pathways, in order to suggest why those ratios are
able to discriminate between the different groups.
N-acetyl-L-aspartate and creatine
In their paper, Harris et al. used the N-acetyl-L-aspartate (NAA) to creatine (Cr) ratio to differ-
entiate between pilocytic astrocytomas and the other tumour types being studied (medulloblas-
toma and ependymoma). The cut-off point was set at 4, with higher ratios indicating that the
tumour was an astrocytoma. This could suggest that the rate of conversion from NAA to Cr is
slower in astrocytomas than it is in medulloblastomas or ependymomas. The Linked Metabolites
search for routes between NAA and Cr produced a relatively diverse directed metabolic graph
(Figure 5.9) made up of more than a dozen generic routes, or over two hundred pathway-specific
routes. Fortunately, a number of these can be rejected based on compartmentalisation issues.
Figure 5.10 shows a route involving the alanine & aspartate and arginine & proline metabolism
pathways. Within it, NAA is converted to aspartate and then on to Cr via L-argininosuccinate,
arginine and guanidinoacetate. Based on the information available in KEGG, this route is quite
plausible; all of the enzymes involved are coded for by the human genome, and it even follows
the recognised entry points between the pathways rather than simply moving between instances
of the same compound. However, the reactions between aspartate and arginine form part of the
urea cycle, a pathway that takes place in the liver, and therefore is unlikely to be appropriate for
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Figure 5.9: Directed metabolic graph produced by Linked Metabolites
showing the routes up to a maximum of 8 steps long from N-acetyl-L-
aspartate (cpd:C01042) to creatine (cpd:C00300).
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Figure 5.10: KEGG pathway diagrams showing a route found by Linked
Metabolites between N-acetyl-L-aspartate and creatine. The route involves
the alanine & aspartate metabolism and arginine & proline metabolism path-
ways. 96
use when explaining the behaviour of metabolites in the brain. While Linked Metabolites allows
the user to specifically remove pathways from its search it would not have helped in this case,
since KEGG’s version of the arginine and proline metabolism pathway contains an instance of
the urea cycle itself and that local version of the pathway could not be removed from the search
without removing the entire arginine and proline metabolism pathway. The nesting of pathways
in this way is a very significant issue, which has no easy resolution since the ways in which path-
ways are defined can have a huge impact on their usefulness in different types of task. KEGG’s
pathways are arranged in a way that best supports manual interpretation by a domain expert;
however for computational tasks, redefining the pathways based on a more physical criteria such
as the conservation of moiety used by Arita would be far more appropriate. This is also a good
illustration of why the results of a Linked Metabolites search are only intended as a guide to
possible chains of reactions that may be involved in an observed biological effect, the manual
checking and interpretation of the results is still an important step.
Figures 5.11 & 5.12 show another two examples of pathway-specific routes between NAA and
Cr. The route in figure 5.11 involves the alanine & aspartate metabolism, pyruvate metabolism
and glycine, serine & threonine metabolism pathways, whereas the route in figure 5.12 replaces
pyruvate metabolism with the glycolysis / gluconeogenesis pathway. However, as with the urea
cycle previously, this is not because they are different routes; it is instead due to KEGG’s
version of the glycolysis / gluconeogenesis pathway including elements of pyruvate metabolism.
Fortunately, unlike the earlier example all these pathways can take place in the brain and
therefore the routes are still valid. The first point of interest to be considered here is that in
the alanine & aspartate metabolism pathway, the route includes a compound (oxaloacetate)
that is involved in the citrate cycle (also know as the TCA cycle), a major component of energy
metabolism. Alterations to energy metabolism between tumour types are common, due to a wide
range of factors such as the aggressiveness of the tumour, the type of tissue it originated in,
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Figure 5.11: KEGG pathway diagrams showing a route found by Linked
Metabolites between N-acetyl-L-aspartate and creatine. The route involves
the alanine & aspartate metabolism, pyruvate metabolism and glycine, ser-
ine & threonine metabolism pathways.
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Figure 5.12: KEGG pathway diagrams showing a route found by Linked
Metabolites between N-acetyl-L-aspartate and creatine. The route in-
volves the alanine & aspartate metabolism, glycolysis / gluconeogenesis
and glycine, serine & threonine metabolism pathways.
99
and the availability of sufficient resources for continued growth. It seems sensible therefore,
that features in pathways responsible for energy metabolism would be able to differentiate
between tumour types to some extent. This hypothesis would also apply to changes involving
the glycolysis / gluconeogenesis pathway, as are suggested by the version of the route in figure
5.12.
Next, we should consider how a slowing of this pathway in pilocytic astrocytomas relative to
medulloblastomas and ependymomas would affect the concentrations of compounds that feature
within it, such as NAA and glycine. If there were a low rate of flow through the pathway (as
we predict to be the case for pilocytic astrocytomas), then there should be a comparatively
low concentration of glycine, owing to the smaller amount of serine, the compound required for
its formation. We would also expect to see a buildup of NAA at the entry to the pathway.
By comparison, in the cases where the pathway is supposed to be flowing more quickly (as
we predict to be the case for medulloblastomas and ependymomas) we should see a larger
concentration of glycine, because more serine will be available, but we should also see a drop in
the concentration of NAA, because it is now able to to enter and be passed down the pathway.
Precisely these results; high NAA and low glycine in astrocytomas, low NAA and high glycine
in medulloblastoma and ependymomas, have been reported in connection with in vitro studies
of these tumour types[97].
As this search is based on compounds that are being used in ratios rather than compounds
selected based on correlation networks, it is quite possible that the difference in their relative
concentrations is not due to an alteration in the biochemistry linking them and is instead due
to some external process. Fortunately, an examination of the directed metabolic graph of these
routes (Figure 5.9) can in this case show us other compounds that owing to the topology of the
graph, should behave in the same way as the compounds involved in the ratios (assuming the
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change in relative concentration of the compounds is due to an alteration somewhere in the routes
Linked Metabolites has identified). In this case, we can see that all the routes involve aspartate
(cpd:C00049) and therefore it should also work as part of the ratio in place of NAA, although it
will of course have a different cut-off value. Likewise guanidinoacetate (cpd:C00581) should act
as an appropriate substitute for Cr. This information could also have been extracted from the
directed metabolic graph automatically using a betweenness centrality algorithm (Section 2.2.5),
a good example of the potential strength of the graph theory approach.
For completeness, a search was also performed for routes running from Cr to NAA although
nothing appropriate was found.
Choline and creatine
Linked Metabolites also found a route between choline (Cho) and Cr, within the glycine, serine
& threonine metabolism pathway (Figure 5.13). This route is well recognised in connection
with tumours due to its role in the formation of S-adenosyl-L-methionine (SAM), a coenzyme
involved in the transfer of methyl groups during DNA methylation (a process that can alter
the regulation of gene expression)[2]. This was previously mentioned in the work on dab liver
tumours (see section 4.3.2). In the classification chart devised by Harris et al. the threshold
values for the Cr/Cho ratio differed significantly between the pilocytic astrocytomas (where
the Cr/Cho ratio was specified as less than 0.35) and the other two tumour types (where the
threshold value used to differentiate between them was 0.75). The lower threshold value for the
pilocytic astrocytomas suggests that the difference in the relative amounts of Cho and Cr in
this tumour type is greater than it is in the other two, and this could be due to either a larger
amount of Cho, a smaller amount of Cr, or a combination of both of these changes. Looking
at the route between the two compounds identified by Linked Metabolites (Figure 5.13), it can
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Figure 5.13: KEGG pathway diagrams showing a route found by Linked
Metabolites between choline and creatine.
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be seen that Cho forms Cr and thus it seems likely that the rate of flow through this pathway
is slower in pilocytic astrocytomas than in the two other tumour types. A lower rate of flow
would explain the greater difference in the relative amounts of the compounds (Cho and Cr) as
a larger amount of Cho will build up at the entry to the pathway. Furthermore, the betaine
to dimethylglycine step of the pathway is the link between it and the formation of SAM, as
mentioned earlier. A lower rate of flow of this pathway in pilocytic astrocytomas, would imply a
lower rate of formation of SAM, and therefore a lower rate of DNA methylation than in the two
other tumour types. It has been reported that the number of hypermethylated (overmethylated)
genes increases with the malignant potential of primary tumours[98], and this fits well with the
low rate of methylation that was predicted (based on Linked Metabolites’ route) for the pilocytic
astrocytomas (a low-grade, and therefore relatively benign, glial tumour[22]) relative to the more
aggressive medulloblastomas.
As the route between Cho and Cr intersects with those found previously between NAA and Cr,
the directed metabolic graph for those routes can be expanded to include it (Figure 5.14). The
fact that the routes intersect adds further weight to the idea that the alterations in the underlying
biochemistry responsible for the difference between these tumour types may be related to the
routes identified by Linked Metabolites. It also suggests that the point of intersection, arginine
(cpd:C00062), may be an interesting target for further investigation.
The Cho and Cr peaks seen in a 1H MRS experiment are actually a combination of the peaks for
several different Cho and Cr containing compounds, merged due to the comparatively low reso-
lution of the current technology. By extending the Linked Metabolites search from a maximum
of 8 to a maximum of 9 steps we can include more of these constituent compounds (Figure 5.15)
and as before, extend our directed metabolic graph (Figure 5.16).
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Figure 5.14: Directed metabolic graph produced by Linked Metabo-
lites showing the routes up to a maximum of 8 steps long from N-
acetyl-L-aspartate (cpd:C01042) and choline (cpd:C00114) to creatine
(cpd:C00300).
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Figure 5.15: Directed metabolic graph produced by Linked Metabolites
showing the routes up to a maximum of 9 steps long from phosphocholine
(cpd:C00588) and glycerophosphocholine (cpd:C00670) to phosphocreatine
(cpd:C02305).
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Figure 5.16: Directed metabolic graph produced by Linked Metabolites
showing the routes up to a maximum of 9 steps long from phospho-
choline (cpd:C00588), glycerophosphocholine (cpd:C00670) and N-acetyl-
L-aspartate (cpd:C01042) to phosphocreatine (cpd:C02305).
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5.4 Discussion
The directed metabolic graphs produced by Linked Metabolites have a range of potential appli-
cations. In metabolomics, multivariate analysis techniques such as PCA and partial least squares
discriminant analysis are commonly used in combination with significance tests to produce a list
of metabolites that contribute to the differences between samples. Subsequent interpretation
of this list, with the aim of finding major metabolic perturbations, is often a time consuming
process whereby the metabolites are “grouped” manually by inspection of known metabolic
pathways. When used in conjunction with clustering metrics, the directed metabolic graphs
produced by Linked Metabolites would offer a rapid, automated solution to this problem.
In the diagnosis and treatment of paediatric brain tumours, MRS can be used to gather quanti-
tative information on the concentrations of key chemicals non-invasively. Analysis of this data
will often indicate pairs of compounds that appear to be elevated in concentration for a particu-
lar tumour type, although small numbers of samples can make achieving statistical significance
difficult. The directed metabolic graphs produced by Linked Metabolites can assist in the study
of these compounds, firstly by providing information on possible biochemical relationships be-
tween them and secondly by helping to identify other compounds that may also have altered in
concentration but that can not be seen using MRS.
Correlation networks, such as those discussed in the previous chapter, are often used to identify
compounds within a dataset that may be involved in common processes. Unfortunately the
presence of a correlation between two compounds does not imply that there is an obvious link
in the underlying biochemistry; as Steuer, Kurths, Fiehn and Weckwerth remarked “...there
is no straightforward connection between the observed correlations and the underlying reac-
tion network. We observe strong correlations between seemingly distant metabolites, whereas
metabolites sharing a common reaction are not necessarily correlated.”[83] By combining infor-
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mation from multiple metabolic pathways and presenting only those routes of potential relevance
to the compounds under investigation, Linked Metabolites can greatly reduce the complexity of
the search for chains of reactions that may be responsible for an observed correlation.
When considering the potential impact of Linked Metabolites, one must first consider how a list
of metabolites can be grouped in a way that is appropriate for answering a particular type of
question. In the simplest case, where purely exploratory work is being undertaken and no further
information is available, all the compounds could be placed in both groups. This would result
in the complete set of routes from every compound to every other being generated, allowing
the broadest possible base for the application of metrics such as motif search. Alternatively,
one may wish to investigate how changes in the concentration of one compound might affect
the concentrations of each of the others; this could be achieved by building a series of directed
metabolic graphs with a single sources and multiple targets, rotating the source compound for
each graph until the entire list of compounds has been covered. In situations where an earlier
analysis of the experimental data has revealed compounds whose concentrations are elevated
relative to another set of compounds, one might wish to use those groups as the basis for two
directed metabolic graphs, one focusing on the routes from the group of compounds with elevated
concentrations to the rest and vice versa. If the previous analysis involved the construction of
correlation networks then several possibilities exist; a directed metabolic graph of all the possible
routes between the compounds could be created as described above and then compared to the
correlation network by searching for common subgraphs. If Pearson correlations were used, then
it may also be appropriate to build graphs showing routes between the positively and negatively
correlated compound groups for each compound. If clearly defined clusters exist within the
correlation network, then these too could be used as the basis for a search.
At this point it is also necessary to consider the limitations of Linked Metabolites and the areas
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in which there is room for development in the future. Firstly, since KEGG does not contain
information on the tissues or cellular compartments in which particular reactions take place,
none of this information is considered during the route search. This is not an issue when the
user has chosen to search for routes that take place within individual metabolic pathways, as the
experimentally determined nature of the reference pathways means that compartmentalisation is
already effectively dealt with; however, when searching across a set of pathways the way in which
Linked Metabolites condenses instances of the same compound from a range of pathways into a
single node means that a pathway that produces a given compound in one type of tissue could
then be linked to a pathway that breaks the same compound down in a completely different area
of the body, without any guarantee that there is a suitable transportation method between the
two. This problem is compounded when in the last stage of the algorithm the identified routes
are combined to form the directed metabolic graphs, again potentially mixing processes taking
place in completely different areas of the body. There are both pros and cons to this behaviour.
The obvious disadvantage is that routes and networks are likely to be generated that contain
errors, linking compounds via intermediaries that can never interact, at least in the context
from which the experimental data was gathered. On the other hand, the original motivation
for the creation of Linked Metabolites was that under certain circumstances such as disease or
external stress, changes to body chemistry might result in novel pathways temporarily becoming
significant and as such “blue-sky” suggestions for interactions that might possibly take place
could provide useful information. This would be particularly relevant in diseases such as cancer,
where the activation and suppression of particular genes may drastically alter the enzymes
present in a particular tissue type, and hence the reactions that could be taking place. Despite
this, there is a strong argument for some form of compartmentalisation to be incorporated into
the search, at least at the tissue level. This could be an optional criteria in the same vein as the
selection of pathways for inclusion, thus allowing the current behaviour to remain if required.
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Unfortunately, such a modification would require the database on which Linked Metabolites’
search is based to be changed from KEGG to something more specialised such as Reactome,
making it more difficult to add support for additional species; a feature that would certainly
be of interest to the biological community, although possibly of less interest to those involved
in medical research. Next we have the issue of how to make the graphs produced by Linked
Metabolites available outside the program, as currently they can only be accessed through the
internal view created after the search has been performed. It would be desirable for the directed
metabolic graphs to be exported in a well-supported graph language, such as the graph modeling
language (GML) so that graph theory tools can be easily applied in other applications; however,
in order to facilitate the testing of the practicalities of the routes, it would also be advantageous
to export the graphs in a format such as SBML, allowing them to be imported into kinetic
modeling packages. In this case it would be sensible to include some other basic information
in the model such as rate constants for each of the reactions, an operation that would not be
difficult if the correct database was used.
The incorporation of the building of correlation networks into the workflow of Linked Metabo-
lites would be an important step in its development for the biological and medical research
communities, allowing researchers to enter their data, view the correlations, and then base their
searches on this information. Figure 5.17 shows how this might be achieved in a future version
of Linked Metabolites, while appendix B contains prototypes for some of the key screens.
One of the key contributions of Linked Metabolites to the field is in the way that it searches for
routes between compounds. Many of the existing database search tools use an all-pairs shortest
paths algorithm for this process, as it is relatively quick to compute. Linked Metabolites by
comparison uses an all simple paths search, which is far more computationally intensive (indeed
for many searches the memory requirements will make the problem intractable) but will find
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Figure 5.17: Flowchart showing how the workflow for a future version of
Linked Metabolites might incorporate the construction of metabolic cor-
relation networks. The coloured blocks represent different screens in the
interface.
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not only the shortest route between a pair of compounds, but also the next shortest and so
on. All of these additional routes, which would be missed by a route search using only an all-
pairs shortest paths algorithm, may in fact contain important information; particularly when
considering situations in which pathways that would normally be dominant are being altered by
disease or stress conditions.
5.5 Conclusions
This chapter has introduced Linked Metabolites, a tool that allows researchers to examine the
relationships between groups of metabolites in the context of the Homo sapiens specific versions
of the metabolic pathways stored in the KEGG database. It has shown a comparison between
the route search capabilities of Linked Metabolites and those of another tool based on the
same database, KEGG PathComp. It gave an example of how a researcher might use Linked
Metabolites to investigate the relationships in the underlying biochemistry between compounds
that appear to differentiate between tumour types. Finally, it has shown how despite some
areas that still need development, the approach used by Linked Metabolites could be applied
in a variety of different fields and how one might go about representing problems in ways that
would be compatible with the use of the tool.
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CHAPTER 6
DIRECTED METABOLIC NETWORKS FROM GENE
EXPRESSION DATA
6.1 Background
Early in this thesis, we described metabolomics as “complementary” to other -omics technologies.
So far we have seen how metabolomics datasets can be used to construct directed metabolic
graphs, with the aim of identifying key features in the underlying biochemistry. These can then
be used to help explain the observed biological changes in the subjects. In this chapter we will
consider how this approach might be extended in the future, using additional information from
other -omics technologies to help us limit the scope of our search of the metabolic pathways still
further. Specifically, we will see how a directed metabolic graph might be used to visualise the
potential metabolic changes resulting from differential gene expression, and how we might then
go about integrating that information into the results of searches from Linked Metabolites.
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6.2 Method
6.2.1 Data
As gene expression data is costly to gather and the early-stage nature of this work required
the use of a relatively small microarray, the raw data used in this chapter was taken from three
previously published studies by Gru¨tzmann et al.[99], Groene et al.[100] and Smirnov et al.[101],
and downloaded from the European Bioinformatics Institute’s (EBI) ArrayExpress service[102].
In all three cases, the data was gathered using either the Affymetrix Human Genome Focus
(HGF) array or a larger array that contains the probes of the HGF array as a proper subset. In
the latter case, the HGF array probes were extracted from the larger dataset and then used for
the construction of the graphs.
6.2.2 Construction of the directed metabolic graphs
The creation of the directed metabolic graphs is performed in two stages; firstly, differentially
expressed genes are selected from the datasets and associated with the enzymes that they encode.
Differential expression is determined through the use of p values (preferably calculated by a non-
parametric test such as the Kruskal-Wallis test) and optionally a two-fold change criteria. Data
processing associated with the microarrays was performed using R[86] and the Bioconductor
package[103]. In the second step, the enzymes associated with the differentially expressed genes
are used to add reactions to the directed metabolic graph based on their involvement as a
catalyst for the reaction. At the time this work was performed, pathway specific directional
information for each reaction was not available in a computer-readable form from the KEGG
database, requiring an enhanced version of the database including this information to be created.
The labour-intensive nature of this process was the main reason for the use of the HGF array.
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Now, the same functionality could be achieved using the XML versions of the pathways, making
the choice of array far less significant.
Since multiple probes on the array might be associated with a single enzyme, reactions are
normally only added to the graph if all the probes associated with them are significantly altered
in expression in the same direction. In the case of particularly noisy datasets meeting this
criteria may be a problem, so a “grey area” could be introduced into the construction process.
In this case, reactions could be added to the graph as long as at least one of the associated probes
is significantly up/downregulated and the others all fall inside the grey area (for example, the
threshold for significance could be set at p of 0.05 but the grey area might extend to p of 0.075).
Compounds are added to the directed metabolic graph if they are either a substrate or a product
for one of the reactions being added. Three directed metabolic graphs are created for each
dataset; one containing those reactions associated with upregulated probes, one containing the
reactions associated with downregulated probes, and a third that contained both the upregulated
and the downregulated reactions. The reactions in the latter graph are colour-coded to indicate if
they were more frequently upregulated (green), downregulated (red) or up/downregulated with
the same frequency (yellow). A flowchart was created to summarise this process (Figure 6.1).
6.3 Results
In order to validate the construction method, directed metabolic graphs were built for three
different types of cancer, pancreatic cancer, colorectal cancer and metastatic breast cancer.
Each graph was built using preexisting, publically available data as described previously, and
the graphs produced were checked for compounds linked to the cancer types in the literature.
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Figure 6.1: Process used for the generation of the directed metabolic
graphs from gene expression data.
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Threshold Mean Node-Node Distance, l Network Diameter
0.01 4.2748 11
0.02 3.9109 11
0.03 3.5565 8
0.04 3.6836 9
0.05 3.8576 9
Table 6.1: The mean node-node distances for the directed metabolic
graphs at each p value along with the graph diameter.
6.3.1 Pancreatic cancer
Pancreatic cancer was the ninth most common malignancy in the United States in 1994[104]
and is one of the most dangerous, with nearly 100% of patients developing metastases and dying
within 5 years[105]. The most common form of the cancer, Pancreatic Ductal Adenocarcinoma
(PDAC), accounts for 90% of all cases[104].
Existing microarray data produced as part of a study into PDAC by Gru¨tzmann et al.[99] was
used to generate directed metabolic graphs for the condition. As the data was gathered using
the Affymetrix U133A microarray, only the subset of the probes that corresponded to the HGF
array were included in the construction of the graphs. The graphs were produced for a range of
p values from 0.01 to 0.05; the graph for p = 0.03 containing reactions associated with both the
upregulated and downregulated probes is shown (Figure 6.2).
Looking briefly at the topology of the graph, the mean distance between node pairs (Table 6.1)
is comparatively small when compared to the network diameters suggesting that these graphs
are small worlds. The degree distribution for the graph shown also displays a power-law with
exponent ≈ 2, in line with figures previously reported for metabolic networks[43].
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Figure 6.2: A directed metabolic graph produced from microarray data of
gene expression in Pancreatic Ductal Adenocarcinoma.
118
Amongst the important nodes in the system is the H+ ion, which has a large number of out-
going links all associated with downregulated probes. This connection pattern would lead to
an increase in the concentration of H+ ions in the system and is consistent with the low extra-
cellular pH frequently seen in expanding tumours[105]. The amino acid glycine also features,
with a pattern of connections suggestive of a drop in its concentration (although without rate
constants in the graph this is a matter of debate); this is consistent with the mutation of the
K-ras oncogene that is seen in the vast majority of patients suffering from this condition[106].
While valine, one of the other possible results of the K-ras mutation is present in the graph,
the clear suggestion is that its concentration would drop. This may however be due to a lack
of coverage of appropriate enzymes (and hence reactions) on the HGF array. Other vertices of
high degree include “usual suspects” such as water, and energy-metabolism related compounds
such as ATP, AMP, pyrophosphate, orthophosphate, NADP+ and NADPH.
6.3.2 Colorectal cancer
The stage of a malignancy is an important determinant of survival. Amongst patients with
colorectal cancer for example, stage 2 tumours have a 20-25% chance of recurrence within 5
years. For stage 3 tumours the rate nearly doubles, rising to 40%[100]. Existing data taken
from a study be Groene et al.[100] was used to construct directed metabolic graphs showing
potential differences in metabolism between stage 2 and stage 3 tumours.
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Figure 6.3: A directed metabolic graph produced from gene expression data
showing potential differences in metabolism between stage 2 and stage 3
colorectal cancers.120
The list of important nodes for the graph at p = 0.06 (Figure 6.3) is dominated by compounds
linked to the TCA cycle (CoA, succinate, succinyl-CoA) and to energy production (ATP, AMP,
NAD+, NADH, NADP+, NADPH), with connection patterns indicative of reductions in the
concentrations of high-energy species such as ATP and increases in the concentrations of lower-
energy species such as AMP. This suggests that the energy requirements of stage 3 colorectal
cancers are very different to those of stage 2, most likely due to the generally accepted view that
stage 3 tumours are more aggressive than stage 2 tumours[100]. As with the PDAC graphs,
H+ ions are shown to be of increasing concentration. The connection pattern surrounding S-
adenosyl-L-methionine indicates a reduction in concentration, and it has been suggested that this
could lead to a decrease in DNA methylation and a loss of the normal controls on proto-oncogene
expression[107]. This process would result in an increased number of oncogenes being over
expressed, which would be consistent with the more aggressive tumour type. The alteration in
DNA methylation is a good example of how important biological processes can still be identified
in graphs despite the type of data used to generate them; here, we see it in a directed metabolic
graph generated from gene expression data, and earlier (in Section 4.3.2) the same process was
seen in the metabolic correlation networks derived from dab liver samples as an alteration in
choline metabolism.
6.3.3 Metastatic breast cancer
An existing HGF array dataset by Smirnov et al.[101] was used to generate a set of directed
metabolic graphs showing potential differences in metabolism between circulating endothelial
cells (a type of cell that forms the internal surface of blood and lymphatic vessels) taken from
healthy volunteers and from patients with metastatic breast cancer.
For the graph at p = 0.05, interesting features include the presence of spermidine and putrescine;
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both of these chemicals are known biomarkers found in the plasma and urine of cancer patients
and are indicative of tumour growth and cell turnover[108]. Folate, a deficiency of which is
increasingly thought to be a factor in the carcinogenesis of many different tumour types in-
cluding breast cancer[109, 110] also features, along with several chemicals (sarcosine, glycine,
and threonine) which are involved in choline metabolism and are immediately downstream of
the choline/betaine oxidation known to be enhanced in malignant breast tumours[111]. Finally,
hydrogen peroxide, which displays a pattern of connections suggestive of an increasing concen-
tration, has been shown to be produced in human tumour cell lines at a far greater rate than
normal[112].
6.4 Discussion
Whilst Linked Metabolites allows researchers to compile directed metabolic graphs showing how
metabolites of interest in a particular condition relate to each other, it is difficult to say how
those relationships behave dynamically. By building additional graphs from gene expression
data, the same information can be viewed from the point of view of the control of the metabolic
pathways, indicating which of the enzymes (that catalyse the metabolic reactions) may be altered
in concentration and therefore cause an associated change in rates of metabolic reactions. It is
important to note that gene expression data is just one more facet of a very complex, integrated
system; however, there is no reason that other data types could not be compiled into directed
metabolic graphs in similar ways.
A major advantage of this approach is that both the metabolic data, from Linked Metabolites,
and the regulatory information, as determined from the gene expression data are in the same
form; as a result they could be combined and processed as a single object. The way in which
this type of data integration is handled will impact on the types of metrics that could be applied
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to the data in the future, and therefore it is important to consider these factors. By simply
taking the areas of intersection between the graphs, for example, you could greatly reduced the
number of chains of reactions that would need to be investigated later by the researcher. Care
must be taken however, as different experimental techniques will have very different coverage
of the system and it is likely that a simple intersection would therefore result in important
information being missed. Instead, it may be more sensible to adopt an approach similar to
Arita’s, in which those routes suggested by both methods would receive a more favourable
weighting in the combined graph. It is also likely that the areas of intersection between the
graphs will not correspond to complete chains of reactions but instead effectively form hot-
spots, where attention should be focused and the most likely routes are likely to fall. Again, this
would suggest that an approach that somehow favourably weighted & highlighted the areas of
intersection between the graphs within the final, combined graph, would be the best solution to
this problem. Unfortunately, a lack of metabolomic and gene expression datasets for the same
conditions prevent us from exploring these ideas any further at present.
123
CHAPTER 7
CONCLUSIONS AND FUTURE WORK
The visualisation and interpretation of data from metabolomics experiments is a complicated
topic. When studies are known to involve a single or a small number of pathways, the colour-
ing of metabolic pathway diagrams based on metabolite concentrations can be a very effective
approach; allowing the researcher to study the relationships between compounds by eye, and in
the context of the underlying biochemistry. However, such studies are far from being the norm
and the low-coverage of the metabolome by many current experimental techniques often mean
that the identification of markers by this approach is ineffective. While statistical tools such as
PCA and significance tests are a great aid to biomarker identification, reducing the number of
metabolites being considered by perhaps an order of magnitude depending on the technology,
the compounds they select as most responsible for the separation between sample groups will not
necessarily be the most appropriate for use as biomarkers and therefore still require validation
with reference to the metabolic pathways.
Metabolic correlation networks present interesting possibilities for both the visualisation of
metabolic datasets and the early stages of the identification of biomarkers. By compiling net-
works for each of the groups of samples in a study, relationships between the various metabolites
can be determined and areas of difference or intersection between the networks used to identify
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potential biomarkers. Correlations might also be used to indicate groups of metabolites that are
potentially involved in the same metabolic pathways, and these can then be used as the basis
for a search. Care must be taken however, since as with other statistical approaches there is no
guarantee that the differences in the networks are specific to the condition being investigated.
The issue of “coverage” of the metabolic pathways also poses problems, and can have a dramatic
impact on the pattern of connections between a group of metabolites in the network. This dif-
ficulty in particular currently makes a more automated approach to biomarker discovery based
on metabolic correlation networks and the metabolic pathways impractical; although as experi-
mental techniques improve, and the coverage of each of the metabolic pathways by experimental
data becomes more predictable, the situation will change.
In the medium term, metabolic correlation networks may have a much more significant role to
play in the analysis of metabolomics datasets, particularly while experimental limitations prevent
the use of time-series methods for the determination of biochemical network structure. This may
well begin with the extension of the underlying correlation analysis to groups rather than pairs
of compounds, creating hyperedges (edges that link more than two compounds together), which
would provide additional information and allow the scope of a search of the metabolic pathways
to be further refined. It is also possible that correlation networks have a role to play in peak
assignment in experimental techniques such as MRS, where issues of resolution mean that it
is not always possible to be sure which compound is responsible for a feature in the spectrum.
By building correlation networks for that data, and determining which other metabolites form
a cluster with the unknown peak, it should be reasonably straightforward to identify it given
there would be a limited number of possible options in that area of the spectrum.
As the major contribution of this work to the field, Linked Metabolites attempts to ease the
task of researchers looking to validate potential biomarkers identified using multivariate statis-
125
tical analysis techniques such as PCA, correlation analysis or other similar approaches. Linked
Metabolites has two key advantages over other similar tools that are already used for this task;
firstly, it offers the possibility of searching for routes between two groups of metabolites. This
is an important advance, since as it becomes increasingly apparent that single compounds are
unlikely to prove specific enough to act as biomarkers on their own, the idea that a researcher
might wish to investigate the links between the compounds forming one “composite” biomarker
and another becomes a distinct possibility and one which would not be possible using single-
source compound or single-target compound searches. Secondly, Linked Metabolites uses an
all simple paths search for the identification of paths between the compound groups. This is
an important advantage over the all simple paths algorithm used by similar packages, since al-
though it is slower in many cases, it has the potential to find a far more diverse range of possible
solutions as demonstrated by its performance relative to that of KEGG PathComp. The way
in which Linked Metabolites combines the metabolic pathways before searching is also unusual,
as it collapses all instances of a particular compound into a single node rather than linking the
pathways only at specific points. This behaviour has both positive and negative aspects, mak-
ing “novel” chains of compounds more likely, but increasing the likelihood that errors will be
introduced. It is important to stress, that while Linked Metabolites is supposed to ease the task
of relating compounds identified in experimental data via the metabolic pathways, the results
still need to be checked and interpreted by a domain expert.
The directed metabolic graphs produced by the Linked Metabolites package open up several
interesting avenues for the advancement of the work. Most promising is the possibility that
through the use of directed metabolic graphs data from other parts of an integrated genomics
study could be merged with the results of the metabolomics study. This would allow information
on the current state of the cell or tissue, as stored in the metabolome, to be combined with
regulatory information, from gene expression, refining the sets of possible reactions further.
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The prospect of using metrics from graph theory, such as betweenness centrality, to identify
other compounds that are likely to be of altered concentration but not necessarily visible to the
experimental technique being used is also important, and could provide an interesting source of
compounds whose behaviour could be used for experimental validation of the biomarkers.
The evolution of the Linked Metabolites software itself would be an important next step in
the process. The development of a tool, probably web-based, which could perform the entire
analysis pipeline is of potentially great use to researchers in the area. As a specific example, it
would be advantageous to be able to move from raw, experimental data, through the production
of correlation networks, and the running of searches against the metabolic pathways in a single
tool. The graphs produced could then be exported in a standard form for use either as the basis
for simulation or fed into other software packages for further analysis, for example motif search.
A new version of the tool would also require a careful rethink of its expected areas of use; in
particular whether a sufficiently large group of users would require the flexibility of switching
between organisms, which is potentially available through the use of the KEGG database as
opposed to the advantages in terms of cellular compartmentalisation that would be gained by
moving to say Reactome. It may be that multiple databases would need to be supported,
that way researchers involved in the medical community could perform more restricted searches
that included compartmentalisation, while others who were interested in species other than
Homo sapiens or who wanted a more “exploratory” answer could use KEGG. With that in
mind, further development of the software will require extensive user assessment by the medical
community and biologists to determine the best way forward and test the current system on a
range of datasets. This work is currently being considered in collaboration with researchers at
the Birmingham Children’s Hospital.
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APPENDIX A
TIME-SERIES METHODS FOR BIOCHEMICAL
NETWORK DISCOVERY
The following appendix summarises a number of different methods for the reconstruction of
biochemical reaction networks from time-series concentration data for the participating com-
pounds. While they are currently of limited applicability to metabolomics (as they require the
reacting system to be forced away from its steady state and as such can only really be used on
data gathered in vitro) they are included here as an interesting future alternative to the use of
metabolic correlation networks and reference pathways.
Chevalier’s method
In 1993, Chevalier et al.[113] published a paper that examined several different experimental
methods for the discovery of unknown or partially unknown reaction mechanisms and compared
their performance based on a model of an oscillating chemical system. Each of the methods
represented a different way to gather time-series information on the concentrations of the com-
pounds making up the system but they all shared the same goal; the formation of a Jacobian
A-1
matrix that described how an alteration in the concentration of one compound would impact
on the concentrations of the others, and from which the reaction network could be determined.
The three methods investigated were pulse perturbation (the sudden introduction of a given
compound into a system in a steady state), concentration shift experiments (in which the con-
centration of a compound feeding into the system is altered) and delayed feedback experiments
(where one of the feeds into the system reflects the concentration of the same compound at
an earlier point in time). Of the three methods, only the delayed feedback experiments failed
to produce an acceptable approximation of the Jacobian for the system. Concentration shift
experiments produced the most accurate version of the Jacobian. Despite producing accurate
models of the system under study, Chevalier’s methods suffered from several flaws that made
them infeasible for large-scale practical use. Firstly and foremost amongst these was the need
to perform multiple experiments in order to allow the perturbation of every compound within
the system. Perturbations also had to be of known magnitude, making it difficult to perturb
the system in ways that were not direct alterations to the concentrations of compounds (such
as temperature changes).
The CMC method
In 1995, Arkin and Ross[114] proposed a method for the identification of reaction pathways
based on multiple correlation analyses of time-series data. The Correlation Metric Construction
(CMC) method differed from Chevalier’s in many ways, but the most significant alteration was
in the way in which the system was forced from the steady state. In Chevalier’s method this was
either done through the use of a pulse perturbation or a series of sustained concentration shifts,
whereas in CMC those compounds that served as the inputs to the reaction pathway were
continuously driven to random concentrations throughout the recording process. The CMC
A-2
method consists of seven steps:
1. A set of measurements of the concentrations of all the compounds in the system are taken
over an extended period, the sampling interval is set to be approximately the time that it
takes for the system to settle back into its steady state and the inputs of the system are
forced to random (Gaussian distributed) concentrations each time a sample is made. The
total experimental time should be long enough to ensure that all possible combinations of
the input compounds have been sampled.
2. The correlation matrix, R(τ) = (rij(τ)) is calculated from the time-series using the equa-
tions:
Sij(τ) = 〈(xi(t)− x¯i)(xj(t+ τ)− x¯j)〉 (A.1)
rij(τ) =
Sij(τ)√
Sii(τ)Sjj(τ)
(A.2)
Where angle brackets denote an average, xi(t) is the tth timepoint of the time-series for
compound i and x¯i is the average of the ith time-series.
3. A clustering algorithm is used to group the compounds in the system based on maximum
correlations between all species, this produces a representation of the system in which
every compound is connected to at least one other.
4. The correlation matrix, R(τ) is converted into a Euclidean distance matrix, D = (dij)
using the transform:
dij = (cii − 2cij + cjj) 12 (A.3)
A-3
cij = max |rij(τ)|τ (A.4)
For those pairs of variables which had a low correlation value the corresponding Euclidean
distance is large and vice-versa.
5. The classical multidimensional scaling method is applied to the distance matrix producing
a consistent configuration of the points, while at the same time establishing the dimen-
sionality of the data. Once projected in 2-D the points will be separated by a distance
which is less than or equal to the actual distance in the distance matrix.
6. An optimisation-based multidimensional scaling algorithm is applied to the dataset which
produces an alternative representation in which the distances between the points may be
less than, equal to or greater than the actual distance values. The optimisation processes is
based on the minimisation of a stress function using a simulated annealing algorithm. The
stress value for both representations is then calculated to determine which is the better
solution.
7. Finally, a cluster analysis is performed on the distance matrix to establish a hierarchy
amongst the interactions of each of the sub-systems within the pathway.
Despite the advantages of Arkin’s method, which not only establishes the structure of the reac-
tion pathway but also highlights areas of tight regulation (the compounds involved lying very
close to each other in the 2-D projection) difficulties do exist; these include the need to know
the inputs to the system under study a priori, the need to continuously alter the concentration
of those compounds throughout the acquisition of the time-series, the selection of the number of
datapoints required for analysis and the problem of assessing the significance of the correlations
calculated.
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D´ıaz-Sierra’s method
In 1999, Dı´az-Sierra et al.[115] published an improved version of Chevalier’s pulse perturbation
method which when applied to well-defined data led to not only the identification of the chemical
processes at work, but also the stoichiometric coefficients and rate constants for each of the
reactions.
The method Chevalier had used to obtain an estimate for the Jacobian was sometimes numer-
ically problematic; an alternative that had since been proposed by Sorribas et al.[116] used an
intermediate matrix Φ as the basis for the calculation of the eigenvalues of the Jacobian. Φ was
calculated from the equation:
δX(ti + h) = Φ · δX(ti) (A.5)
Unfortunately, the calculation of the eigenvalues of Φ was sensitive to noise and rounding errors
in the experimental data. To avoid this problem, Dı´az-Sierra adapted Sorribas’ method by using
Φ as a term in:
J =
1
h
[I + (Φ− I)] (A.6)
When expanded in its Taylor series, the above could then be used to calculate the Jacobian as
long as the sampling period, h was constant and long enough to capture the greatest relaxation
time for the system.
J =
1
h
[(Φ− I)− (Φ− I)(Φ− I)
2
+ . . . ] (A.7)
The reaction mechanisms are determined from the Jacobian as follows:
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1. The matrix of coefficients, JijXj,0 is created by the element-wise multiplication of each
column of the Jacobian by its equivalent steady state concentration. The number of generic
reaction steps can then be determined by counting the number of independent entries. For
each of the remaining entries, linear relationships should be expressed in the form:
n∑
ij
I
(r)
ij (JijXj,0) = 0 r = 1, . . . , p (A.8)
where I(r)ij are low integers and p is the number of dependent entries.
2. The linear equations are then substituted into:
m∑
s=1
αjsγisνs,0 = JijXj,0 i, j = 1, . . . , n (A.9)
to obtain equations in the form:
n∑
ij
I
(r)
ij (αjsγis) = 0 r = 1, . . . , p, s = 1, . . . ,m (A.10)
3. While these equations can not be used to directly infer the values of α and γ, they do
imply that α and γ can be expressed as parameter-dependent functions of the form:
αis(µ1, . . . , µR), γis(µ1, . . . , µR) (A.11)
The values of µR can then be determined by the substitution of the above into the first
set of equations in step 2, followed by the use of the known rates at which compounds are
being fed into the system.
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Schmidt’s method
Recently, Schmidt et al.[117] have produced a method specifically tailored towards the identi-
fication of small scale biochemical networks based on time-series in which both the magnitude
and effects of the perturbation are unknown. Their method has several important characteristics
in that it not only produces an estimate for the continuous time Jacobian of the system, but
also produces estimates for the perturbation to individual system components and can indicate
elements of the system possessing faster dynamics than can be captured by the experimental
sampling time; however to date it has only been applied to in silico systems.
The method assumes a fixed sampling time ∆T and that the perturbation to the system is con-
stant between two sampling points. It also assumes that in a system consisting of n components,
the concentration of every component is measured at each timepoint and that a minimum of
n+ 2 timepoints are recorded with the first being taken before the perturbation is applied.∗
The estimates for Ad, the discrete time Jacobian of the system and ∆u, the constant unknown
perturbation to the system are obtained simultaneously from ∆xk, the measurement vectors
using the equation:
[Aˆd,∆uˆ] = RMT (MMT )−1 (A.12)
Where R, the result matrix assuming m relative timepoints is given by:
R = [ ∆xm ∆xm−1 . . . ∆x2 ] (A.13)
∗This is the absolute minimum and in real-world systems more timepoints are needed and multiple experiments
should be performed from the same steady state. The first recorded timepoint is only used as a reference from
which to calculate the relative values, so n+ 2 recorded timepoints will result in n+ 1 relative timepoints in the
calculations.
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and M , the measurement matrix is given by:
M = [ ∆xm−1 ∆xm−2 . . . ∆x1 ] (A.14)
Since all of the values are relative, a system from which you have recorded information at six
timepoints will therefore result in (4)×(4) result and measurement matrices.
When r experiments are performed the result and measurement matrices are constructed as
follows:
R = [ R1 . . . Rr ] M =

M1 M2 . . . Mr
1 0 . . . 0
0 1 . . . 0
...
...
. . .
...
0 0 . . . 1

(A.15)
and the estimate becomes:
[Aˆd,∆uˆ1, . . . ,∆uˆr] = RMT (MMT )−1 (A.16)
where ∆uˆr is the estimate of the perturbation in experiment r.
Aˆzoh, the estimate of the continuous time Jacobian is then calculated from the estimated discrete
time Jacobian using the inverse form of the zero-order hold discretisation:
Aˆzoh =
1
∆T
logm
(
Aˆd
)
(A.17)
where logm
(
Aˆd
)
denotes the matrix logarithm of the estimation of the discrete time Jacobian.
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The identification of system components with dynamics that are faster than can be captured
by the chosen experimental sampling time is an important issue since if not removed from
the analysis they lead to inaccurate representations of the system. The identification process is
relatively straightforward, first the singular values of the measurement matrix,M are calculated.
If θ1 is relatively close to zero compared to the other singular values of the system then the chosen
sampling time is too short relative to the system’s dynamics. Next, the singular vector which
corresponds to the singular value identified must be examined, the most dominant element of
which indicates the component with the fast dynamic. This component is then removed from
the system and the network for the remaining elements calculated as normal.
The extraction of the network underlying the system is now performed in the same way as for
the other methods.
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APPENDIX B
PROTOTYPE SCREENS FOR THE WEB VERSION OF
LINKED METABOLITES
The following appendix presents a number of prototype screens for a web-based version of Linked
Metabolites. The new version could expand on the functionality of its predecessor by allowing
the entry of experimental datasets and the construction of metabolic correlation networks, thus
guiding the users selection of search groups.
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Figure B.1: The data entry screen (part 1). Here the user defines the
dataset by specifying a name, the number of samples and the metabolites
measured.B
-2
Figure B.2: The data entry screen (part 2). Here the user enters the
concentrations for each metabolite.B
-3
Figure B.3: The network review screen. Here the user can view the corre-
lation network for their dataset. The threshold values can be selected using
the sliders. On the right hand side of the screen the user can edit the search
groups while still viewing the correlation network.
B
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Figure B.4: The network group selection screen. Here the user checks
the groups they have set. They may then either confirm that they want to
proceed with the search, or choose to manually add additional metabolites.B
-5
Figure B.5: The group selection screen. Here the user may edit the search
groups independently of the correlation analysis.
B
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Figure B.6: The pathway selection screen. Here the user selects the path-
ways that will be included in the search.
B
-7
GLOSSARY
-
-omics An area of study in biology focusing on a particular set of compounds such as
genomics (the study of the genome) or metabolomics (the study of the metabolome).
A
apoptosis The process of cell death.
B
betweenness centrality The proportion of the paths through a graph that feature a given node
or edge. High betweenness centrality values may indicate a bottleneck.
biofluid A fluid such as blood or urine that can be taken from a biological specimen.
biomarker A compound or group of compounds that in particular concentrations can be used
to determine an organism’s condition (e.g. determine whether it has a particular
disease).
BioPAX A data exchange format for metabolic pathway information.
Bonferroni correction A method of correcting for multiple significance tests by dividing the
significance value by the number of tests to be performed against it.
C
clustering coefficient The extent to which the neighbours of a node are also connected to each
other.
correlation coefficient A measure of how closely two vectors are related. In biology this is
usually the concentrations of two compounds across a set of samples.
Ddegree The total number of edges or arcs incident on a node in a graph.
degree distribution The range of probabilities showing how likely it is a node in the graph will
be connected to a given number of edges.
directed metabolic graph A graph showing metabolites and the directed flow of reactions
between them.
F
false discovery rate A method of selecting the significance threshold based on an expected
frequency of false-positive results.
G
glycolysis A metabolic pathway in which sugars are broken down to form energy.
graph theory A branch of mathematics that studies the properties of graphs.
I
in vitro Within the glass. In vitro experiments are performed on biological samples that are
outside an animal or plant.
in vivo Within an organism. In vivo imaging techniques include x-rays, where bones are
examined without removing them from the individual.
indegree The number of arcs heading into a node in a graph.
K
KEGG See Kyoto Encyclopedia of Genes and Genomes.
Kruskal-Wallis A non-parametric, variance-based test for statistical significance. Since it is
non-parametric, the Kruskal-Wallis test has no underlying assumption that the data
follows a normal distribution.
Kyoto Encyclopedia of Genes and Genomes A biological database that contains, amongst
other things, a set of metabolic pathway diagrams.
LLinked Metabolites A graphical tool for route search within the metabolic pathways and the
construction of directed metabolic graphs.
M
Magnetic Resonance Imaging An in vivo branch of NMR that uses the water within tissues
to create images of the body.
Magnetic Resonance Spectroscopy An in vivo branch of NMR that focuses on the detection
of metabolites.
metabolic correlation network A graph in which nodes, representing metabolites, are linked
by edges that represent a significant correlation between the concentrations of the
two in an experimental dataset.
metabolic pathway A set of reactions that perform a particular metabolic function such as
the release of energy from sugars.
metabolome The complete set of low molecular weight compounds involved in metabolism.
metabolomics The study of the set of low molecular weight compounds involved in metabolism.
microarray A piece of apparatus that can be used to measure gene expression.
motif search The extension of triadic census to n-node subgraphs.
MRI See Magnetic Resonance Imaging.
MRS See Magnetic Resonance Spectroscopy.
N
necrosis The premature death of cells and tissue.
NMR See Nuclear Magnetic Resonance.
Nuclear Magnetic Resonance A way of determining the molecules that are present in a sample
based on the magnetic properties of some atomic nuclei (e.g. hydrogen).
O
outdegree The number of arcs leaving a node in a graph.
PPajek A program for the analysis of networks.
PCA See Principal Components Analysis.
Principal Components Analysis A statistical technique that describes a dataset with a large
number of dimensions in terms of a smaller number of vectors that represent the
variance in the original data.
Python A scripting language.
R
Reactome A metabolic pathway database.
S
SBML See the Systems Biology Markup Language.
scale-free network A graph with a degree distribution that follows a power-law. Amongst
other interesting features, scale-free systems display a higher than normal resilience
to random node failures.
simple path A path between two nodes that does not loop back on itself at any point.
small-world network A graph with a small average path length between nodes compared to
that of a random graph of similar size and density.
Systems Biology Markup Language An xml standard for the exchange of biological models.
T
TCA cycle A metabolic pathway, also known as the citric acid cycle or the Krebs cycle, that
is key to energy metabolism and electron transport.
triadic census A survey of a graph for the frequencies of the sixteen possible non-identical,
three-node subgraphs and the comparison of those frequencies against a set of ex-
pected values.
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